Section 3 of 6
Product information and disease description
520 evidence topics · 256 sources
Product description
Phase of product development
Summary: development and regulatory status
As of November 2026, the axitinib intravitreal implant (AXPAXLI, OTX-TKI) is investigational and is not approved in any country, and the FDA has not approved AXPAXLI as a product name. It is in a phase 3 registrational program for neovascular age-related macular degeneration (nAMD), the SOL program, which comprises SOL-1 (superiority versus a single injection of aflibercept 2 mg), SOL-R (non-inferiority versus aflibercept 2 mg every 8 weeks; 640 participants randomized), and the open-label extension SOL-X. The FDA issued a Special Protocol Assessment agreement letter for the SOL-1 trial design on October 30, 2023, and agreement letters for modifications on January 22, 2024 and February 24, 2025. In its feedback on SOL-R, the FDA noted that one superiority trial and one non-inferiority trial is generally acceptable as the basis of an NDA in wet AMD.
Because axitinib is FDA-approved for non-ophthalmic indications, the sponsor plans to submit a New Drug Application under section 505(b)(2), which it states may shorten the FDA review by up to 60 days; a May 2026 Type C meeting and a September 2026 pre-NDA meeting addressed the content of the submission. On November 9, 2026, the sponsor stated that the submission remains “on track for 4Q 2026” and will follow an interim SOL-R Week 52 safety analysis to be conducted in the fourth quarter of 2026. The NDA is to be supported by SOL-1 Week 52 efficacy data, SOL-1 and interim SOL-R Week 52 safety data, and confirmatory evidence; together with the 170 participants who received the implant in SOL-1, the interim analysis is intended to bring the aggregate safety dataset to more than 300 participants with at least one year of follow-up. SOL-R efficacy data are not part of the planned submission. The quarterly report for the period ended June 30, 2026 stated a plan to submit SOL-1 Year 2 safety data at the 120-day safety update, and the November 2026 announcement states a plan to submit, during the NDA review, data from participants who received multiple implant injections in both phase 3 trials, to support repeat dosing on the label.
SOL-R topline results are expected in the first quarter of 2028. In August 2026, the company stated that the SOL-R primary endpoint, non-inferiority to aflibercept 2 mg at Week 56, remained unchanged; in November 2026, it reported that the primary endpoint had been moved to Week 40, with key secondary endpoints kept at Weeks 56 and 96, so that all participants pass the primary endpoint visit before the interim Week 52 safety analysis. The sponsor describes a potential U.S. launch in 2027 if approved. No FDA expedited program designation, European Medicines Agency submission, or other ex-U.S. regulatory filing was identified.
Special Protocol Assessment agreement and modifications for SOL-1
FDA feedback on the SOL-R trial and a one superiority plus one non-inferiority trial package
Planned NDA content after the May 2026 Type C meeting
Repeat-dosing data planned for the 120-day safety update
Regulatory status: Submission planned; NDA planned for the fourth quarter of 2026
SOL-R protocol amendment and revised topline timing
FDA expedited program designations, EMA submissions, and other ex-U.S. regulatory filings
No evidence found.
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Ocular Therapeutix
Product names and development code
Intervention name in trial registrations
Class context: approved oral axitinib
Nonproprietary name for the implant
No evidence found.
Dosage forms and strengths
Dosage form: polyethylene glycol hydrogel containing micronized axitinib
Strength in phase 3 trials: 450 µg (0.45 mg), second-generation formulation
Second-generation formulation: more soluble form of axitinib
Strengths studied in phase 1 trials: first-generation 200, 400, and 600 µg implants
Delivery device: single-use applicator
Commercial presentation, packaging, and storage conditions
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO ATC classification of axitinib (oral antineoplastic)
| ATC code | Name | DDD | Unit | Route |
|---|---|---|---|---|
| “L01EK01” | “axitinib” | “10” | “mg” | “O” |
WHO ATC ophthalmic antineovascularisation agents (S01LA): listed substances
AHFS classification and ophthalmic ATC code for the axitinib intravitreal implant
No evidence found.
Indication
Label sought by the sponsor
Population studied in the pivotal superiority trial
Pharmacology
Mechanism of action
Intracellular VEGF receptor tyrosine kinase inhibition
Receptor targets of axitinib: review
“Axitinib is a second-generation TKI that potently targets the VEGFR1, VEGFR2, and VEGFR3 tyrosine kinase receptors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It also inhibits the PDGFR α and PDGFR β tyrosine kinases and c-Kit receptors at higher concentrations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Class context: mechanism of action in the oral axitinib (INLYTA) label
Contrast with extracellular anti-VEGF ligand binding
Hydrogel drug-release mechanism
ELUTYX hydrogel platform chemistry
Rationale for sustained delivery of a tyrosine kinase inhibitor
Combined VEGF and PDGF pathway inhibition: in vitro and rat choroidal neovascularization models
“Axitinib inhibited neovascularization better than anti-VEGF and/or anti-hPDGF-B mAb in the in vitro models demonstrating that combined inhibition of both VEGF and PDGF pathways may be synergistic in treating wet-AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
Intracellular kinase inhibition and hydrogel delivery of axitinib: independent review
“Tyrosine kinase inhibitors (TKIs) are small molecules that act at the intracellular level to inhibit receptor tyrosine kinase by preventing tyrosine kinase phosphorylation and the downstream signaling cascade.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, TKIs are capable of inhibiting all isoforms of VEGF as well as other receptor tyrosine kinases including fibroblast growth factor receptor and platelet-derived growth factor receptor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Axitinib binds to the intracellular ATP-binding site of VEGFR-1, VEGFR-2, and VEGFR-3, thereby inhibiting receptor phosphorylation” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cross-linked polyethylene glycol polymer chains form a hydrogel, allowing diffusion of the micronized molecule.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for single-agent dual VEGF and PDGF receptor inhibition in choroidal neovascularization
“Axitinib is a small molecule tyrosine kinase inhibitor mainly targeting VEGFR1-3 and PDGFR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Targeting VEGFR1-3, axitinib offers an anti-VEGF spectrum as broad as aflibercept, but also adds PDGFR and c-Kit inhibition” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In our hands, axitinib was not only capable of a modulation of VEGF-mediated endothelial cellular function, but also expanded current treatment options by inhibition of pericytes attributable to its impact on PDGF-signaling, as pericytes do not express c-Kit” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From a future perspective, axitinib as a single substance offering dual anti-VEGF/PDGF inhibition might allow for an easier, better-tolerated application.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Kinase selectivity and potency: sponsor cell-based and biochemical assays
TIE2 inhibition: comparative study sponsored by a competitor developer
“HotSpot™ assay and TIE2 IC 50 values showed that only axitinib potently inhibited TIE2 (up to 89%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the three TKIs, only axitinib potently inhibited TIE2 which is an undesired trait as TIE2 is essential for vascular stability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VEGFR2 potency above IC50: comparative in vivo angiogenesis findings
“This experiment demonstrates that in a VEGF-dependent study, any of the three TKIs when used at the VEGFR2 IC 50 value will achieve the desired efficacy and when levels higher than IC 50 are utilized the result is little to no enhancement in the effect; hence, the higher potency for VEGFR2 inhibition reported for axitinib relative to vorolanib and sunitinib appears to be of no benefit when compounds are present at concentrations at or above the receptor IC 50 value for that particular TKI.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vascular leakage in a VEGF challenge rabbit model: 0.45 mg second-generation implant
Pericyte phenotype with combined VEGF and PDGF receptor inhibition
Preclinical ocular tolerability: 6-month GLP toxicology study in non-human primates
Preclinical repeat dosing every 6 months in non-human primates
Exposure-response in humans: clinical activity relative to preclinical tissue concentrations
Onset of anatomic activity: Australian phase 1 trial
Kinase selectivity of axitinib compared with sunitinib: independent review
“In vitro, individual TKIs differ in their VEGFR-binding affinity, receptor selectivity profiles, and off-target inhibition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Axitinib, for example, is a potent and selective inhibitor of VEGFR-1, VEGFR-2, and VEGFR-3 with minimal activity against other kinases, whereas sunitinib has broader activity, also targeting platelet-derived growth factor receptors (PDGFRs), c-Kit, and FLT3.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These differences in molecular selectivity may influence not only efficacy and durability but also safety profiles when these agents are applied to ocular tissues via sustained-release platforms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Concentration-dependent inhibition of endothelial cell and pericyte proliferation and migration by axitinib in vitro
“Human endothelial cells (HUVEC) and human pericytes (hPC-PL) were treated with axitinib doses ranging from 1.0 ng/ml to 10 μg/ml.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In HUVEC, a significant decrease in cellular proliferation compared to untreated controls could be observed from 0.1 to 10 μg/ml axitinib” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In pericytes, stimulation with 20 ng PDGF-BB resulted in an approximately 6-fold migratory increase” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On regular Cultrex, treatment with 0.5, 1, and 2.5 μg/ml axitinib showed a significant decrease of vessel-associated area by 48, 50, and 62% respectively” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“IC50 values of antiproliferative activity were generally lower on endothelial cells than on pericytes. This correlates well with the pharmacological profile of axitinib, which offers VEGFR2-inhibition with an IC50 of 0.2 nM versus 1.6 nM for PDGFR” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
In vitro tolerability range of axitinib on endothelial cells and pericytes
“In HUVEC, no statistically significant decrease of metabolic activity and cell count compared to controls treated with vehicle could be observed from 1.0 ng/ml to 7.5 μg/ml axitinib” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In pericytes, no reduction of metabolic activity could be observed within the range of solubility of axitinib up to 10 μg/ml” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All effects on both cell lines were observed in non-toxic concentrations of axitinib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetics
Designed release duration
Implant bioresorption in humans
Systemic exposure in humans: Australian phase 1 trial
Ocular tissue concentrations in non-human primates: first-generation implants
Ocular tissue concentrations through 12 months in non-human primates: sponsor summary
First-generation versus second-generation implant pharmacokinetics in monkeys and rabbits
Interspecies scaling of implant bioresorption
Release kinetics: independent review
Class context: oral axitinib (INLYTA) absorption, distribution, and half-life
Class context: oral axitinib (INLYTA) metabolism and excretion
Vitreous and plasma concentrations of the 450 µg implant in humans
No evidence found.
Vitreous clearance of tyrosine kinase inhibitors and the rationale for sustained release: independent review
“Rapid vitreous clearance of existing VEGF inhibitors limits durability to 1-4 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Combining TKIs with sustained release platforms, such as hydrogel or polyvinyl alcohol, allow for the sustained release of the molecules and the potential for extended durability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“OTX-TKI is administered via a 25-gauge intravitreal injection and is designed to be completely bioresorbable and have biologic activity over 9-12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
FDA-approved prescribing information, contraindications, boxed warnings, and REMS
Not applicable.
Key safety findings in the pivotal trial through Week 52
Vitreous floaters and relation to hydrogel bioresorption
Injection-procedure endophthalmitis in the U.S. phase 1 trial
Class context: retinal vein occlusion with systemic tyrosine kinase inhibitors, including oral axitinib
“Three patients were on imatinib, five patients on axitinib, two on ibrutinib, and one patient on regorafenib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This series highlights a possible association between TKI therapy and RVO, underscoring the need for awareness in patients with vascular risk factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Special populations
Age of randomized participants in SOL-1
Pregnancy, breastfeeding, and contraception: SOL-X exclusion criterion
Monocular patients and fellow-eye vision: exclusion criteria
Advanced lesions with scar, fibrosis, or atrophy: exclusion criterion
Prior intraocular inflammation: SOL-X exclusion criterion
Pediatric use, renal or hepatic impairment, and lactation data for the implant
No evidence found.
Drug/Drug, drug/disease interactions
Effects of other drugs on axitinib intravitreal implant
Clinical drug interaction studies with the intravitreal implant
No evidence found.
Systemic exposure after intravitreal administration as context for interaction potential
Class context: oral axitinib (INLYTA) with strong CYP3A4/5 inhibitors
Class context: oral axitinib (INLYTA) with strong CYP3A4/5 inducers
Class context: oral axitinib (INLYTA) pH-dependent solubility
Effects of axitinib intravitreal implant on other drugs
Clinical drug interaction studies with the intravitreal implant
No evidence found.
Class context: oral axitinib (INLYTA) effects on CYP enzymes and transporters
Preclinical systemic exposure with repeat intravitreal dosing
Dosing and administration
Dosage
SOL-1: single dose after aflibercept loading, with redosing at Weeks 52 and 76
SOL-X: long-term dosing every 24 weeks
U.S. phase 1 trial: single 600 µg first-generation implant with one aflibercept injection
Redosing interval informed by bioresorption and disease reactivation
Proposed labeled dose, dosing interval, and dose modification
No evidence found.
Administration
Needle gauge and applicator
Injection site in preclinical studies
Aseptic technique, pre-injection preparation, and post-injection monitoring instructions
No evidence found.
Access and distribution
Manufacturing
Commercial field and reimbursement team
Reimbursement risk stated by the sponsor
Expanded access program, HCPCS code, distribution channel, and REMS
No evidence found.
Coverage restrictions on anti-VEGF agents in United States commercial and Medicare Advantage plans
“A recent assessment of US commercial and MA health plans as of 2024 revealed substantial heterogeneity in coverage restrictions for these agents, including requirements for step therapy protocols, prescriber type, and patient subgroup criteria, with approximately 65% of commercial plans imposing restrictions beyond US Food and Drug Administration labeling.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, some plans excluded coverage for specific agents, such as brolucizumab, and varying reauthorization criteria further complicate access.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These payer-driven differences likely reinforce the geographic disparities observed in Medicare utilization patterns in 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Co-prescribed/Concomitant therapies
SOL-1: supplemental aflibercept rescue
SOL-R: anti-VEGF screening doses, aflibercept loading, and rescue criteria
Phase 1 trials: concomitant anti-VEGF injection
U.S. phase 1 trial: prior anti-VEGF treatment requirement
Topical corticosteroids for intraocular inflammation in SOL-1
Prophylactic corticosteroids with implant administration
Concomitant systemic medication use in studied participants
No evidence found.
Effect of axitinib intravitreal implant on quality measures
IRIS Registry QCDR measure IRIS63: exudative AMD gain of visual acuity
IRIS63 denominator: treatments counted as anti-VEGF agents
Product-specific effect on quality measures
No evidence found.
Product comparison
Summary
No head-to-head trial has compared the axitinib intravitreal implant with aflibercept 8 mg, faricimab, the ranibizumab port delivery system, vorolanib intravitreal insert (DURAVYU, EYP-1901), or gene therapies. The only randomized comparisons are with aflibercept 2 mg: a single implant versus a single aflibercept 2 mg injection in SOL-1 (superiority), and implant every 24 weeks versus aflibercept 2 mg every 8 weeks in SOL-R (non-inferiority, results expected in the first quarter of 2028); SOL-R also includes an aflibercept 8 mg every 24 weeks arm with a planned Week 96 superiority comparison. Approved extended-durability comparators reached approval through non-inferiority trials against aflibercept 2 mg every 8 weeks (aflibercept 8 mg in PULSAR, 1009 treated participants; faricimab in TENAYA and LUCERNE, 1329 randomized participants) or monthly ranibizumab (port delivery system in Archway, 418 participants). Labeled maintenance intervals are every 8 weeks for aflibercept 2 mg, every 8 to 16 weeks for aflibercept 8 mg (every 20 weeks may be considered after one year), up to every 16 weeks for faricimab after 4 monthly doses, and refills every 24 weeks for the port delivery system, which carries a boxed warning for endophthalmitis and requires prior response to at least two anti-VEGF injections. SOL-1 enrolled participants selected for response to two aflibercept loading doses, with mean baseline BCVA of 80.8 and 79.2 letters, whereas the comparators' pivotal trials enrolled participants with lower baseline vision; cross-trial comparisons of durability or treatment burden are therefore limited, and the sponsor's own cross-trial treatment burden table is labeled as illustrative. Among other sustained-delivery tyrosine kinase inhibitors, the phase 3 LUGANO trial of vorolanib intravitreal insert did not meet its non-inferiority primary endpoint in the full dataset (August 2026). Gene therapies surabgene lomparvovec (ABBV-RGX-314) and 4D-150 are in phase 3, with topline data expected in the fourth quarter of 2026 and in 2027, respectively. Preclinical kinase-profiling studies sponsored by the developers of axitinib and vorolanib products reached different conclusions about axitinib inhibition of TIE2.
Competitive landscape described by the sponsor
Aflibercept 2 mg (EYLEA): labeled nAMD dosing
Aflibercept 8 mg (EYLEA HD): labeled nAMD dosing
Aflibercept 8 mg: PULSAR phase 3 results at Week 48
Faricimab: TENAYA and LUCERNE phase 3 results
“BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mean change 5·8 letters [95% CI 4·6 to 7·1] and 5·1 letters [3·9 to 6·4]; treatment difference 0·7 letters [-1·1 to 2·5]) and LUCERNE (6·6 letters [5·3 to 7·8] and 6·6 letters [5·3 to 7·8]; treatment difference 0·0 letters [-1·7 to 1·8]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ranibizumab port delivery system (SUSVIMO): indication, dosing, and boxed warning
Ranibizumab port delivery system: Archway phase 3 results
“Adjusted mean change in BCVA score from baseline averaged over weeks 36 and 40 was +0.2 letters (standard error [SE], 0.5 letters) in the PDS Q24W arm and +0.5 letters (SE, 0.6 letters) in the monthly ranibizumab arm (difference, -0.3 letters; 95% confidence interval, -1.7 to 1.1 letters).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Prespecified ocular adverse events of special interest were reported in 47 patients (19.0%) in the PDS Q24W arm and 10 patients (6.0%) in the monthly ranibizumab arm, which included, in the former arm, 4 (1.6%) endophthalmitis cases, 2 (0.8%) retinal detachments, 13 (5.2%) vitreous hemorrhages, 6 (2.4%) conjunctival erosions, and 5 (2.0%) conjunctival retractions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vorolanib intravitreal insert (DURAVYU, EYP-1901): LUGANO phase 3 topline results
Suprachoroidal axitinib (CLS-AX): phase 1/2a OASIS trial
Axitinib-based products in development
“Several axitinib-based therapies are in development for wet AMD and other retinal diseases, including Axpaxli (also known as Ocular Therapeutix-TKI, Ocular Therapeutix), CLS-AX (Clearside Biomedical), AR-14034 (Alcon), and GLK-401 (Glaukos).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gene therapy: surabgene lomparvovec (ABBV-RGX-314) pivotal trial timing
Gene therapy: 4D-150 pivotal trial timing
Sponsor cross-trial treatment burden comparison at approximately 1 year
| Product and trial | Reduction versus aflibercept 2 mg, loading doses included | Reduction versus aflibercept 2 mg, loading doses not included |
|---|---|---|
| Faricimab, TENAYA/LUCERNE phase 3 | “14% (6.4 vs 7.4)” | “46% (2.4 vs 4.4)” |
| Aflibercept 8 mg, PULSAR phase 3 | “29% (5.49 vs 7.7)” | “47% (2.49 vs 4.7)” |
| 4D-150, PRISM phase 2b | “50% (3.97 vs 8)” | “51% (2.97 vs 6)” |
| Axitinib intravitreal implant, SOL-1 with SOL-R rescue criteria | “56% (3.95 vs 9)” | “72% (1.95 vs 7)” |
Baseline vision in SOL-1 compared with other nAMD phase 3 trials
Hydrogel compared with other polymer implant platforms
Durability and treatment burden across sustained-delivery TKIs: independent reviews
“Out of all the drugs explored in this section, thus far, EYP 1901, OTX-TKI and CLS-AX have shown good safety but moderate durability signals on PhI/IIa studies on nAMD patients who are sub-optimal responders to standard of care.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proportion of PULSAR participants maintaining extended aflibercept 8 mg intervals to week 48
“A total of 251 (79%) of 316 patients in the aflibercept 8q12 group and 239 (77%) of 312 patients in the aflibercept 8q16 group maintained their assigned dosing regimen up to week 48. Overall, 523 (83%) of 628 patients who received aflibercept 8 mg maintained at least 12-week dosing intervals up to week 48.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The minimum interval for all patients was 8 weeks, and dosing intervals could not be extended within the first year of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline vision and eligibility differences that limit cross-trial comparison with PULSAR
“the mean baseline BCVA ETDRS letter score was 59·6 (SD 13·3), approximately Snellen equivalent 20/63” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the PULSAR study enrolled patients with a larger total lesion size of up to 12 disc areas and required foveal involvement, whereas patient eligibility in TENAYA and LUCERNE was restricted to those with lesion sizes of up to 9 disc areas without foveal involvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Differences between trials in the criteria used to implement regimen modifications, the timepoints at which dose-modification criteria were assessed, and in study populations, limit cross-trial comparisons.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Faricimab dosing-interval distribution at week 48 in TENAYA and LUCERNE
“At week 48, approximately 80% of faricimab-treated patients in both TENAYA and LUCERNE were on 12-week or 16-week dosing intervals, with 107 (34·0%) patients in TENAYA and 104 (32·9%) patients in LUCERNE on extended dosing regimens of every 12 weeks, and 144 (45·7%) patients in TENAYA and 142 (44·9%) patients in LUCERNE on 16-week dosing” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator choice and masking-related limits on durability comparison in the faricimab trials
“The registrational phase 3 trials of faricimab for nAMD were not designed for head-to-head comparison of faricimab’s durability versus aflibercept because extended fixed 12-week or fixed 16-week dosing regimens have not been studied in double-masked phase 3 registrational trials for aflibercept.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fixed 8-week aflibercept dosing, which was used in the pivotal phase 3 trials of aflibercept, was therefore the most appropriate regimen against which to evaluate noninferiority of a new treatment, especially considering the potential for extended dosing with faricimab at up to 16-week repeating intervals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, the assessment of the potential for faricimab to reduce treatment burden and improve quality of life might also be limited by the fact that at the time of the primary analysis, all patients returned for monthly visits to maintain masking.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Injections and treatment completion over 2 years in TENAYA and LUCERNE
“Of 1326 patients treated across TENAYA/LUCERNE, 1113 (83.9%) completed treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moving to the T&E regimen during year 2 resulted in significantly fewer injections of faricimab compared with aflibercept Q8W dosing (median, 10 injections vs. 15 injections from baseline through year 2; 3 injections vs. 6 injections during the year 2 T&E phase); however, per the design of the study, aflibercept was given at fixed intervals throughout the 2-year study period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Sustained-delivery tyrosine kinase inhibitor platforms compared: independent review
“EYP-1901 is a sustained-delivery implant that combines Durasert E with a multikinase pan-VEGF inhibitor vorolanib. The implant is designed to release vorolanib at near zero order kinetics for 9 months and to be completely bioerodible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among these emerging therapies, platforms combining intravitreal sustained-release technology with pan-VEGF inhibition (eg, EYP-1901, OTX-TKI, CLS-AX) currently appear the most balanced in terms of efficacy, safety, and durability. However, the clinical value of pan-VEGF inhibition remains uncertain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Despite evidence suggestive of the beneficial biologic effect of X-82, the phase 2 trial was terminated early because of concerns regarding elevated liver enzyme elevations and high study discontinuation rate because of AEs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At this time, the sponsor has discontinued further investigation of GB-102.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Endophthalmitis risk attributed to the implantation procedure and to indwelling devices
“Review of the case details including surgical videos identified 8 cases where the surgical procedures may have contributed to the risk of developing endophthalmitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A large scleral incision (>3.5 mm) resulting in an inadequate seal around the implant, may increase the risk of endophthalmitis occurring soon after the PDS surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, these rates are similar to what has been observed for FA implants versus systemic therapy (1.3% vs. 0%, respectively) over 24 months in patients with noninfectious uveitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vision course after implantation in Archway
“Patients treated with the PDS Q24W experienced a transient and reversible postsurgical drop of approximately 1 ETDRS line in vision after implant insertion, with vision returning to baseline by week 8.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A similar proportion of patients in the PDS Q24W arm (80.5%) and the monthly ranibizumab arm (82.2%) showed a BCVA of 69 letters or better at the average of weeks 36 and 40 (Table S5, available at www.aaojournal.org).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place of product in therapy
Disease description
Definition and etiology
AMD definition: AAO Preferred Practice Pattern
AMD definition: CONAN consensus nomenclature
“A condition in patients, typically beyond 50 years of age, in which the structure and function of the macula deteriorates. A salient characteristic is the accumulation of extracellular deposits including subretinal drusenoid deposits, basal linear, and basal laminar deposit. These eyes may demonstrate neovascularization or atrophy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In AMD, the neovascularization may start in the outer retina, and therefore, the term choroidal neovascularization is not appropriate for the class.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical classification: Beckman Initiative for Macular Research
“Persons with medium drusen (≥ 63-<125 μm), but without pigmentary abnormalities thought to be related to AMD, should be considered to have early AMD. Persons with large drusen or with pigmentary abnormalities associated with at least medium drusen should be considered to have intermediate AMD. Persons with lesions associated with neovascular AMD or geographic atrophy should be considered to have late AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Five-year risks of progressing to late AMD are estimated to increase approximately 100 fold, ranging from a 0.5% 5-year risk for normal aging changes to a 50% risk for the highest intermediate AMD risk group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical classification: AREDS categories used by the AAO Preferred Practice Pattern
Late-stage classification: geographic atrophy and exudative neovascular AMD
“In the late stages of AMD, 2 distinct manifestations emerge. One is the development of confluent areas of atrophy involving photoreceptors and retinal pigment epithelium, known as geographic atrophy. The other is the growth of abnormal blood vessels in the macular region, referred to as neovascular AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neovascular AMD causes visual change when these new blood vessels leak, which may cause subretinal and intraretinal fluid accumulation, hemorrhages, and fibrosis. This condition is known as exudative neovascular AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Macular neovascularization subtypes: CONAN definitions
Macular neovascularization subtypes: AAO Preferred Practice Pattern
Polypoidal choroidal vasculopathy: frequency by population and presentation
“Although a minority subtype in white populations, it accounts for approximately half of MNV seen in Asia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Asian persons, the typical presentation comprises isolated macular involvement, unilateral, and male preponderance, whereas in white persons, bilateral involvement, female preponderance, and the neovascular lesion originating from the peripapillary region are more common.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Type 3 neovascularization: origin and terminology
“The neovascularization in RAP may originate not only from deep retinal capillaries but also from the choroid. We therefore propose the more descriptive term "Type 3 neovascularization" for this entity to emphasize the intraretinal location of the vascular complex and distinguish this type from the two types of neovascularization previously described by J. Donald Gass in his classic text.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Distribution of neovascular subtypes at diagnosis: US single-physician cohort
“A total of 232 patients (266 eyes) fit the inclusion criteria. Mean age was 86.3 years; 67.7% of eyes (180/266) were from female patients, and 95.5% (254/266) were from white patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With FA+OCT, 39.9% (106/266), 9.0% (24/266), 34.2% (91/266), and 16.9% (45/266) were type 1 (sub-retinal pigment epithelium), type 2 (subretinal), type 3 (intraretinal), and mixed neovascularization (NV), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: multifactorial disease
“AMD is a multifactorial disease related to aging, genetic susceptibility, and environmental risk factors such as cigarette smoking; it develops as a consequence of disruption of the normal homeostatic mechanisms of the retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Age-related macular degeneration is a multifactorial disorder, with dysregulation in the complement, lipid, angiogenic, inflammatory, and extracellular matrix pathways implicated in its pathogenesis. More than 50 genetic susceptibility loci have been identified, of which the most important are in the CFH and ARMS2 genes. The major non-genetic risk factors are smoking and low dietary intake of antioxidants (zinc and carotenoids).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: AAO Preferred Practice Pattern summary
Risk factors: age
“A meta-analysis of AMD incidence in 10 populations of White individuals from Europe, Australia, and the United States with approximately 135 000 person-years of follow-up reported that late-stage AMD was associated with an incidence of 0.3 per 1000 in those aged 55to 59 years, 5.7 per 1000 in those aged 75 to 79 years, and 36.7 per 1000 in those aged 90 years or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: cigarette smoking
“Cigarette smoking is an independent risk factor for AMD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“increasing the risk of AMD by twofold to fourfold” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Smoking cessation reduces the risk of AMD, and after 20 years of cessation, the risk of AMD is similar to that in non-smokers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a large prospective cohort study of 61 862 women over a 12-year follow-up period, 1 case of AMD developed per 1708 person-years among women who currently smoked 25 or more cigarettes per day compared with 1 case per 3740 person-years among those who had never smoked.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: meta-analysis of clinical risk factors for late AMD
“A systematic review identified 18 prospective and cross-sectional studies and 6 case control studies involving 113,780 persons with 17,236 cases of late AMD that included an estimate of the association between late AMD and at least one of 16 pre-selected risk factors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increasing age, current cigarette smoking, previous cataract surgery, and a family history of AMD showed strong and consistent associations with late AMD. Risk factors with moderate and consistent associations were higher body mass index, history of cardiovascular disease, hypertension, and higher plasma fibrinogen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: heritability and major genetic loci (CFH and ARMS2-HTRA1)
“Estimated heritability of late-stage AMD is approximately 71% (estimate for additive risk, 0.71 [95% CI, 0.18-0.88] in 840 participants from a US twin study of AMD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“indicating that approximately 71% of the risk of AMD is genetic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Risk factors: genome-wide association study and a genetic signal specific to neovascular AMD
“Analyzing 16,144 patients and 17,832 controls, we identify 52 independently associated common and rare variants” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While wet and dry AMD subtypes exhibit predominantly shared genetics, we identify the first signal specific to wet AMD, near MMP9” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Neovascular age-related macular degeneration
United States: annual incidence of neovascular AMD in White adults aged 50 years and older
“Annual incidence (estimated from prevalence) of late AMD in American whites was 3.5 per 1000 aged ≥50 years (95% credible interval 2.5, 4.7 per 1000), equivalent to 293 000 new cases in American whites per year (95% credible interval 207 000, 400 000). Incidence rates approximately quadrupled per decade in age. Annual incidence GA rates were 1.9 per 1000 aged ≥50 years, NVAMD rates were 1.8 per 1000. Late AMD incidence was 38% higher in women vs men (95% credible interval 6%, 82%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: 3-year incidence of exudative AMD in Medicare beneficiaries
“Overall, the 3-year incidence of exudative AMD is estimated to be between 9.4 per 1000 and 11.4 per 1000 Americans age 65 and older (depending on ascertainment criteria), based on those diagnosed and treated by ophthalmologists for the condition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Women were found to have a slightly higher incidence of AMD than men using all ascertainment criteria (P < 0.001), and white Americans were found to have a fivefold-to-sixfold higher ascertainment criteria than black Americans (P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: 15-year cumulative incidence in the Beaver Dam Eye Study
“The 15-year cumulative incidence was 14.3% for early AMD (the presence of either soft indistinct drusen or the presence of pigmentary abnormalities together with any type of drusen) and 3.1% for late AMD (presence of exudative AMD or geographic atrophy).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals > or = 75 years of age at baseline had significantly (P<0.01) higher 15-year incidences of the following characteristics than people 43 to 54 years of age: larger drusen (125 mum in diameter, 24.1% vs 10.6%), soft indistinct drusen (18.7% vs 6.5%), retinal pigmentary abnormalities (20.2% vs 3.7%), exudative macular degeneration (4.4% vs 0.4%), and pure geographic atrophy (3.2% vs 0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: 8-year incidence of late AMD by race and ethnicity
“A prospective cohort study of 3811 participants aged 46 to 86 years residing in the US reported an 8-year incidence of late-stage AMD of 0.4% for people who were Black, 2.2% for people who were Chinese, 0.8% for people who were Hispanic, and 4.1% for people who were White.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: newly diagnosed neovascular AMD in the IRIS Registry, 2016 to 2021
“Among the 918 759 patients with nAMD (61.5% female, 82.3% White), male, Black, and Hispanic patients demonstrated nAMD at younger ages (P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the mean ± standard deviation (SD) age at nAMD presentation was 80.2 ± 9.1) years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Europe: pooled annual incidence of late AMD
“In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression to late AMD: AREDS simplified severity scale
“Risk factors are summed across both eyes, yielding a 5-step scale (0-4) on which the approximate 5-year risk of developing advanced AMD in at least one eye increases in this easily remembered sequence: 0 factors, 0.5%; 1 factor, 3%; 2 factors, 12%; 3 factors, 25%; and 4 factors, 50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression to late AMD: updated simplified severity scale incorporating reticular pseudodrusen
“As the final Simplified Severity Scale, the five-year progression rates for levels 0–4, respectively, were 0.3%, 4.3%, 11.6%, 26.7%, and 50.0%, for participants without RPD at baseline, and 2.8%, 8.0%, 29.0%, 58.7%, and 72.2%, for participants with RPD at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression to neovascular AMD: AREDS eyes free of late AMD at baseline
“In the 5-year follow-up period (years 2-7), 486 of 7223 (6.7%) of eyes developed NV AMD, 339 of 7253 (4.7%) developed CGA, 726 of 7246 (10.0%) developed any GA, 2622 of 7095 (37.0%) had at least 2-line BCVA loss, and 1494 of 7155 (20.9%) had at least 3-line BCVA loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression from early AMD in the AREDS
Fellow-eye conversion: AAO Preferred Practice Pattern summary
Fellow-eye conversion: CATT participants receiving anti-VEGF therapy
“Among 1185 CATT participants, 727 (61%) had no CNV in the fellow eye at enrollment. At two years, CNV had developed in 75 (20.6%) of 365 patients treated with ranibizumab and 60 (16.6%) of 362 patients treated with bevacizumab (absolute difference 4.0%, 95% confidence interval (−1.7%, 9.6%); p=0.17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence was not associated with genotype on rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3) (p > 0.35).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fellow-eye conversion: UK National Health Service database
Fellow-eye conversion: Fight Retinal Blindness! registry
United States: annual incidence of neovascular AMD in White adults aged 65 years and older and 80 years and older
“In those aged 65 years and older the annual incidence rate for late AMD is 7.8 per 1000 (95% credible interval 5.5, 10.6), 4.3 per 1000 for GA (95% credible interval 2.9, 6.2), and 3.9 per 1000 for NVAMD (95% credible interval 2.7, 5.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In those aged 80 years and older the annual incidence rates per 1000 are 19.4 (95% credible interval 13.8, 26.2), 10.9 (95% credible interval 7.2, 16.1), and 9.9 (95% credible interval 6.8, 14.0), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This corresponds to approximately 293 000 new cases of late AMD each year (95% credible interval 207 000, 400 000), and 160 000 (95% credible interval 107 000, 234 000) and 148 000 (95% credible interval 103 000, 207 000) for GA and NVAMD, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: late AMD and neovascular AMD incidence rates in women compared with men
“For all age groups (except the youngest), women have a slightly higher annual incidence rate of late AMD (4 per 1000, 95% credible interval 2.3, 6.6) than men (2.4 per 1000, 95% credible interval 1.4, 4.2; Table 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In those aged 65 years and older the incidence rates of NVAMD within each 5-year age group are higher in women than in men.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Under 70 years of age the number of incident cases is similar in men and women.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: rate of increase in late AMD incidence per decade of age by estimation method
“A meta-analysis of incidence studies showed that the incidence rate for late AMD triples per decade increase in age (rate ratio 2.9; 95% credible interval 2.6, 3.2, Table 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In proportionate terms, annual incidence rates from prevalent studies suggest a quadrupling in risk per decade, whereas the meta-analysis of incidence studies suggests a tripling.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although late AMD incidence increases log-linearly with age, the absolute number of incident cases of late AMD decreases beyond the age of about 85 years because of increased mortality.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: 3-year incidence of exudative AMD in Medicare beneficiaries by ascertainment criterion
“As shown in Table 4, the 3-year estimated incidence of exudative macular degeneration in the Medicare population ranges from 0.37% (95% confidence interval [CI], 0.35, 0.38) to 1.14% (95% CI, 1.12, 1.16), depending on the ascertainment criteria chosen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Extrapolating from the published report, the 5-year incidence of exudative AMD in persons aged 65 and older is 1.48% (95% CI, 0.80%, 2.16%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: person-level rather than eye-level counting in the Medicare incidence estimate
“In this study, we have attempted to measure the 3-year per-person incidence, as opposed to the per-eye incidence of exudative AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of information on laterality in the Medicare database makes it impossible to estimate the incidence of exudative AMD per eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: age gradient and coverage limits of the Medicare claims-based estimate
“As shown in Figure 2, the incidence of exudative AMD increases linearly with age, but seems to level off at the oldest age group. There is no biological basis to suggest a decrease in true incidence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 20% of Medicare beneficiaries aged 65 to 74 years and 18% of beneficiaries aged 75 to 85 years join Medicare HMOs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Neovascular age-related macular degeneration
United States: prevalence of early and late AMD in 2019
“For 2019, we estimated that there were 18.34 million people 40 years and older (95% uncertainty interval [UI], 15.30-22.03) living with early-stage AMD, corresponding to a crude prevalence rate of 11.64% (95% UI, 9.71-13.98). We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prevalence of late-stage AMD increased with age from 0.02% (95% UI, 0.01-0.05) among those 40 to 44 years (Figure 3) to 11.39% (95% UI, 6.45-18.46) among people 85 years or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The gender- and age-standardized rate of late AMD for non-Hispanic White individuals 40 years and older was 1.03% (95% UI, 0.65-1.52).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: late AMD definition used in 2019 prevalence estimates
United States: prevalence in 2000 and projection to 2020
“The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Owing to the rapidly aging population, the number of persons having AMD will increase by 50% to 2.95 million in 2020.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: NHANES 2005 to 2008
“In the civilian, noninstitutionalized, US population aged 40 years and older, the estimated prevalence of any AMD was 6.5% (95% confidence interval, 5.5-7.6) and the estimated prevalence of late AMD was 0.8% (95% confidence interval, 0.5-1.3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
United States: projection to 2050 and share of AMD that is neovascular
Global: pooled prevalence and projections to 2040
“Analysis of 129,664 individuals (aged 30-97 years), with 12,727 cases from 39 studies, showed the pooled prevalence (mapped to an age range of 45-85 years) of early, late, and any age-related macular degeneration to be 8.01% (95% CrI 3.98-15.49), 0.37% (0.18-0.77), and 8.69% (4.26-17.40), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The projected number of people with age-related macular degeneration in 2020 is 196 million (95% CrI 140-261), increasing to 288 million in 2040 (205-399).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Global: prevalence by ancestry
“The pooled prevalence of any AMD is approximately 8.69% (95% credible interval [CrI], 4.26-17.40) in persons aged 45 to 85 years, with a prevalence in people who are of European origin of 12.33% (95% CrI, 6.46-22.75), 10.43% (95% CrI, 5.27-20.01) in people who are of Hispanic origin, 7.53% (95% CrI, 3.80-14.89) in people who are of African origin, and 7.38% (95% CrI, 3.80-14.89) in people who are of Asian origin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Europe: pooled prevalence in adults aged 60 years and older
Global: prevalence of vision impairment due to AMD, 1990 to 2021, with forecasts to 2050
“Globally, the number of individuals with vision impairment due to AMD more than doubled, rising from 3·64 million (95% uncertainty inverval [UI] 3·04-4·35) in 1990 to 8·06 million (6·71-9·82) in 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The burden of vision impairment due to AMD is projected to increase to about 21·34 million in 2050.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Untreated neovascular AMD: systematic review and meta-analysis of visual acuity loss
“Four thousand three hundred sixty-two untreated neovascular AMD patients from published interventional studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean VA change in logMAR progressed from 0.1 (1 line lost) at 3 months to 0.3 (2.7 lines lost) after 12 months and 0.4 (4 lines lost) after 24 months. The proportion of patients who developed severe vision loss (>6 lines) from baseline increased from 21.3% at 6 months to 41.9% by 3 years. The proportion of patients with VA worse than logMAR 1.0 (20/200 Snellen) increased from 19.7% at baseline to 75.7% by 3 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A doubling of the visual angle of presenting VA may be expected to occur in the year after initial presentation in eyes with untreated neovascular AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Untreated neovascular AMD: MARINA sham-injection arm
“Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Untreated neovascular AMD: severe vision loss in the MARINA sham-injection arm through 24 months
“At 12 months, very few patients receiving ranibizumab had severe vision loss (30 letters or more) from baseline (0.8% of the 0.3-mg ranibizumab group and 1.2% of the 0.5-mg ranibizumab group compared with 14.3% of the sham-injection group); at 24 months, 3.4% of the 0.3-mg ranibizumab group and 2.5% of the 0.5-mg ranibizumab group had severe vision loss compared with 22.7% of the sham injection group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Untreated neovascular AMD: VISION sham-injection arm
“In the group given pegaptanib at 0.3 mg, 70 percent of patients lost fewer than 15 letters of visual acuity, as compared with 55 percent among the controls (P<0.001). The risk of severe loss of visual acuity (loss of 30 letters or more) was reduced from 22 percent in the sham-injection group to 10 percent in the group receiving 0.3 mg of pegaptanib (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Neovascular AMD without anti-VEGF therapy: ANCHOR verteporfin photodynamic therapy arm
“Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
End stage of untreated exudative disease: fibrosis and disciform scar
“Without treatment, exudative MNV typically results in extensive fibrosis with severe central vision loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history before neovascularization: 5-year and 10-year risk by simplified severity score
Nonexudative macular neovascularization preceding exudation
Mortality: systematic review and meta-analysis (10 studies)
“Late AMD was associated with elevated rates of all-cause (nine studies, hazard ratio (HR) 1.20, 95% confidence interval, CI, 1.02-1.41) and cardiovascular mortality (six studies, HR 1.46, 95% CI 1.13-1.98), but early AMD was not (all-cause mortality, 10 studies, HR 1.06, 95% CI 0.98-1.14; cardiovascular mortality, five studies, HR 1.12, 95% CI 0.96-1.31).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: meta-analysis of 13 population-based cohort studies
“The risk of all-cause mortality and cardiovascular mortality associated with early AMD were 1.08 (1.00-1.18) and 1.05 (0.89-1.24), and the associations with late AMD were 1.23 (1.11-1.36) and 1.28 (1.04-1.57), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: neovascular AMD and anti-VEGF therapy in AREDS2
“During follow-up (median 5 years), 368 (9%) of the 4203 AREDS2 participants died. Participants with neovascular AMD in 1 eye at baseline had a statistically significant increased risk for mortality compared to participants with no or few drusen (hazard ratio [HR] 1.56, 95% confidence interval [CI], 1.21–2.01; p-value [p]<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants who received anti-vascular endothelial growth factor therapies for neovascular AMD had decreased mortality compared with those who did not (HR: 0.71, 95% CI 0.57–0.88; p=0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: advanced AMD in the AREDS
“During median follow-up of 6.5 years, 534 (11%) of 4753 AREDS participants died. In fully adjusted models, participants with advanced age-related macular degeneration (AMD) compared with participants with few, if any, drusen had increased mortality (relative risk [RR], 1.41; 95% confidence interval [CI], 1.08-1.86). Advanced AMD was associated with cardiovascular deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Retinal structures affected in AMD
“In AMD, important neural, structural, and vascular layers undergo degenerative changes leading to cell death. These include the photoreceptors, which are specialized neurons that convert light into electrical signals that are processed in the visual cortex to form images; the retinal pigment epithelium, a cell layer that is adjacent to the photoreceptors; the Bruch membrane, a collagenous layer that supports and separates the retinal pigment epithelium from the choroid; and the choriocapillaris, which is a fine meshwork of capillaries located in the innermost aspect of the choroid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Drusen formation: aging, inflammation, lipid deposition, and oxidative stress
“These aging-related alterations, combined with chronic inflammation, altered lipid and lipoprotein deposition, increased oxidative stress, and impaired extracellular matrix maintenance, lead to extracellular deposits in the neurosensory retina, retinal pigment epithelium, and Bruch membrane” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VEGF-A and VEGFR2 signaling in neovascularization
“Neovascularization is thought to be induced by increased expression of hypoxia-driven vascular endothelial growth factor A (VEGF-A), which is released in response to stimuli such as oxidative stress and complement activation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“VEGF promotes angiogenesis by binding to its receptor VEGFR2 and activating downstream pathways that promote endothelial cell proliferation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
VEGF expression in surgically excised choroidal neovascular membranes
“Surgically removed subfoveal fibrovascular membranes from 18 eyes were analyzed for the expression of VEGF mRNA and protein using in situ hybridization and immunohistochemistry, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most specimens expressed both VEGF mRNA and protein.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Results indicate that VEGF may be of pathogenetic importance for the development of the choroidal neovascularization (age-related macular degeneration)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All three choroidal neovascular membranes and all seven epiretinal membranes stained positive for vascular endothelial growth factor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because expression of some growth factors is stimulated by hypoxia, their localization within choroidal neovascular membranes suggests that hypoxia may be an etiologic factor for choroidal as well as for retinal neovascularization.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Signaling model: oxidized lipoprotein debris, RPE-derived VEGF, and choroidal endothelial activation
“One predominant component of oxidized lipoprotein debris that accumulates in BrM in neovascular AMD is 7-ketocholesterol, which can induce angiogenesis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“7-Ketocholesterol is thought to activate microglia to release cytokines, such as TNF, which mediates VEGF expression in RPE cells and its release preferentially from the basal aspects” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the generated ROS presumably also diminish the RPE barrier integrity and permit secreted VEGF entry into the retina, which promotes choroidal endothelial cell migration, proliferation and eventually MNV formation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Transition from nonexudative to exudative MNV: PDGF, angiopoietin, and VEGF signaling
“The conversion of non-exudative MNV to exudative MNV is likely to be a major disease transition point in neovascular AMD. Signalling pathways that contribute to this transition may include alterations in MNV pericyte coverage (as potentially regulated by PDGF and TIE2–ANG1 signalling)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“changes in the local balance of vascular trophic factors (such as VEGF and PEDF)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“or modulation of complement function” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PDGF-mediated pericyte stabilization and combined VEGF and PDGF receptor inhibition in vitro
“Platelet-derived growth factor (PDGF) signaling is pivotal to pericyte-induced stabilization of choroidal neovascularizations (CNV), and causes partial anti-VEGF resistance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Axitinib inhibits angiogenesis in endothelial cells and pericytes via VEGFR and PDGFR modulation in vitro.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exudation: leakage, fluid, and breakdown of the blood-retinal barrier
“However, in many eyes, increased intralesional hydrostatic pressure coupled with breakdown of the outer blood–retinal barrier leads to exudation into the subretinal space. Intraretinal fluid accumulation may occur in conjunction with breakdown of the external limiting membrane, or VEGF expression may induce intraretinal leakage independently.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrosis: wound-healing response and the VEGF to connective tissue growth factor balance
“Fibrosis is a part of the wound-healing response” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“that results from numerous cytokines and factors such as transforming growth factor β1, pigment epithelial growth factor, and connective tissue growth factor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Higher levels of VEGF in relation to connective tissue growth factor may promote vascular growth, whereas decreases in the ratio may lead to increased fibrosis, scarring, and contracture of that tissue.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Complement dysregulation: CFH Y402H
Causes of vision loss in neovascular AMD: leakage, hemorrhage, fibrosis, and atrophy
“The main causes of vision loss in neovascular AMD include those directly related to the new vessels such as leakage, hemorrhage, and fibrosis. Another important cause of vision loss, particularly in treated cases, is atrophy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Age-Related Eye Disease Study 2, 40% of patients demonstrating MNV also showed atrophy at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pericyte recruitment and anti-VEGF resistance in choroidal neovascularization
“While VEGF mainly regulates endothelial cells, PDGF signaling is crucial for cells of the vascular wall, i.e., pericytes and smooth muscle cells” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pericytes migrate along a PDGF gradient towards neovessels, proliferate, and associate with the endothelial tubes, leading to vascular stabilization via physical contact, VEGF, and the Ang1/Tie2 system” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, PDGF-recruited pericytes are known to support endothelial cells with paracrine VEGF and other pro-survival factors which cannot be complexed as effectively by current anti-VEGF agents” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
AAO Preferred Practice Pattern: history and examination
“Metamorphopsia” (opens the source at this quote in a new tab)
“Decreased vision” (opens the source at this quote in a new tab)
“Scotoma” (opens the source at this quote in a new tab)
“Photopsia” (opens the source at this quote in a new tab)
“Difficulties in dark adaptation” (opens the source at this quote in a new tab)
AAO Preferred Practice Pattern: optical coherence tomography
AAO Preferred Practice Pattern: optical coherence tomography angiography
AAO Preferred Practice Pattern: fluorescein angiography indications and risks
AAO Preferred Practice Pattern: indocyanine green angiography for polypoidal choroidal vasculopathy
Imaging modalities for diagnosis and management
| Imaging modality | Quoted considerations |
|---|---|
| Optical coherence tomography | “Most suitable for monitoring treatment effects in exudative neovascular AMD”View highlighted excerpt for this quote |
| Fluorescein angiography | “Gold standard for assessing exudative neovascular AMD due to visualization of dye leakage”View highlighted excerpt for this quote |
| Fluorescein angiography | “Invasive with intravenous dye injection and risk of anaphylaxis”View highlighted excerpt for this quote |
| Optical coherence tomography angiography | “Noninvasive and a potential replacement for fluorescein angiography in detecting neovascular AMD”View highlighted excerpt for this quote |
Sensitivity and specificity of monitoring tests for exudative neovascular AMD in fellow eyes
| Diagnostic test | Quoted sensitivity and specificity, % (95% CI) |
|---|---|
| Self-reported vision changes | “Sensitivity: 4.2 (1.6-9.8); specificity: 97.0 (94.6-98.5)”View highlighted excerpt for this quote |
| Amsler chart | “Sensitivity: 33.7 (25.1-43.5); specificity: 81.4 (76.4-85.5)”View highlighted excerpt for this quote |
| Visual acuity | “Sensitivity: 30.0 (22.5-38.7); specificity: 66.3 (61.0-71.1)”View highlighted excerpt for this quote |
| Biomicroscopic examination | “Sensitivity: 53.8 (44.8-62.5); specificity: 97.6 (95.3-98.9)”View highlighted excerpt for this quote |
| Optical coherence tomography | “Sensitivity: 91.7 (85.2-95.6); specificity: 87.8 (83.8-90.9)”View highlighted excerpt for this quote |
Optical coherence tomography versus fluorescein angiography: systematic review
“Twenty-two studies (2 abstracts and 20 articles) enrolling 2124 participants were identified” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a meta-analysis of TD-OCT studies, sensitivity and specificity (95% CI) were 88% (46-98%) and 78% (64-88%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Diagnosis of nAMD should not rely solely on OCT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Optical coherence tomography angiography versus fluorescein angiography: meta-analyses
“The total population included in the meta-analysis comprised 553 eyes, with a cumulative sensitivity and specificity of 85.9% (95% CI 81.9-89.3%) and 89% (95% CI 83.5-93.2%), respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The evidence obtained does not demonstrate the superiority of OCTA over FA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Detection of new-onset MNV in high-risk fellow eyes: AMD DOC study
“The sensitivity of each modality for detecting CNV was: OCT 0.40 (95% confidence interval [CI], 0.16-0.68), supervised Amsler grid 0.42 (95% CI, 0.15-0.72), and PHP 0.50 (95% CI, 0.23-0.77).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among fellow eyes of individuals with unilateral CNV, FA remains the best method to detect new-onset CNV.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Home monitoring for earlier detection: HOME study
“Seven hundred sixty-three participants were randomized to device monitoring and 757 participants were randomized to standard care and were followed up for a mean of 1.4 years between July 2010 and April 2013.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis achieved statistical significance, with the participants in the device arm demonstrating a smaller decline in visual acuity with fewer letters lost from baseline to CNV detection (median, -4 letters; interquartile range [IQR], -11.0 to -1.0 letters) compared with standard care (median, -9 letters; IQR, -14.0 to -4.0 letters; P = 0.021), resulting in better visual acuity at CNV detection in the device arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AAO Preferred Practice Pattern: self-monitoring and prompt evaluation of new symptoms
Polypoidal choroidal vasculopathy: OCT-based diagnostic criteria without indocyanine green angiography
“For the diagnosis of PCV, the combination of 3 OCT-based major criteria (sub-retinal pigment epithelium [RPE] ring-like lesion, en face OCT complex RPE elevation, and sharp-peaked PED) achieved an area under the receiver operating characteristic curve of 0.90. Validation of this new scheme in a separate subset 80 eyes achieved an accuracy of 82%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis in US practice: ICD-10 coding of active choroidal neovascularization
Clinical presentation - signs and symptoms
Visual distortion: metamorphopsia as a presenting symptom
“A retrospective survey including 217 patients revealed that about 40% sought assistance due to visual distortion (straight lines appearing curved); approximately 38% of patients reported a decline in vision, characterized by blurred vision, loss of visual acuity, or difficulty focusing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Onset: sudden symptoms with rapid worsening
Central vision loss: visual acuity at presentation in the IRIS Registry
“Overall, 25.9% of patients with nAMD demonstrated normal or near-normal vision (20/40 or better) at presentation. Most patients (60.0%) showed mild to moderate vision impairment (VA between 20/40 and 20/200), and 14.1% of patients showed severe vision impairment (VA worse than 20/200; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among Hispanic patients with nAMD, 20.5% showed normal or near-normal vision and 19.6% showed severe vision impairment at presentation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central visual field loss: scotoma
“The exudative stage of neovascular AMD (also known as ‘wet AMD’) becomes apparent when these new vessels leak or rupture, resulting in fluid accumulation and/or haemorrhages, and distortion and deterioration in vision.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Low-luminance and contrast symptoms: difficulty in dim light
“An early symptom of AMD is difficulty performing tasks under low light conditions and in low-contrast surroundings,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“such as in poorly illuminated rooms. Patients typically seek help when experiencing more pronounced symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Functional symptoms: reading, driving, and face recognition
“When AMD becomes symptomatic in both eyes, or if there is already reduced vision in one eye when the other eye becomes symptomatic, patients are more likely to report a loss in their ability to read, drive, or perceive fine details, including facial expressions. Having good vision in one eye, however, may mask symptoms in the other eye.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Entoptic symptoms: photopsia
“The top 16 included posterior vitreous detachment (PVD) in 39.7% of eyes; retinal tear in 8.9% of eyes; neovascular age-related macular degeneration (AMD) in 7.9% of eyes” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The photopsias from neovascular AMD are more centrally located (83%), quick and repetitive (79%), seen in light (73%) and dark (63%) environments, have no inciting stimuli (84%), and are more likely to be nonwhite (40%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual hallucinations: Charles Bonnet syndrome
“We identified 18 studies with data on >4303 patients with AMD. We found an overall prevalence of CBS of 15.8% (95% confidence interval: 11.0%-21.2%). When looking at consecutively recruited patients with neovascular AMD from the clinic, prevalence of CBS was 7.2% (95% confidence interval: 4.3%-10.6%). Among visitors to visual rehabilitation centres, prevalence of CBS was 31.6% (95% confidence interval: 21.7%-42.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fundus signs: hemorrhage, exudation, fluid, and pigment epithelial detachment
Fundus signs: polypoidal choroidal vasculopathy
Fundus signs: type 3 macular neovascularization
Asymptomatic disease: symptom-based detection in fellow eyes
Long-term morbidity
Blindness: leading cause among White adults in the United States
“Based on demographics from the 2000 US Census, an estimated 937 000 (0.78%) Americans older than 40 years were blind (US definition). An additional 2.4 million Americans (1.98%) had low vision. The leading cause of blindness among white persons was age-related macular degeneration (54.4% of the cases), while among black persons, cataract and glaucoma accounted for more than 60% of blindness.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Blindness: share of severe visual loss in the United States
Blindness and moderate to severe vision impairment: global estimates for 2020
“In 2020, 1.85 million (95%UI: 1.35 to 2.43 million) people were estimated to be blind due to AMD, and another 6.23 million (95%UI: 5.04 to 7.58) with MSVI globally. High-income countries had the highest number of individuals with AMD-related blindness (0.60 million people; 0.46 to 0.77).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The leading global causes of blindness in those aged 50 years and older in 2020 were cataract (15·2 million cases [9% IU 12·7-18·0]), followed by glaucoma (3·6 million cases [2·8-4·4]), undercorrected refractive error (2·3 million cases [1·8-2·8]), age-related macular degeneration (1·8 million cases [1·3-2·4]), and diabetic retinopathy (0·86 million cases [0·59-1·23]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Legal blindness: incidence before and after introduction of anti-VEGF therapy
“The incidence rate of legal blindness attributable to AMD in citizens aged ≥50 years decreased from 52.2 cases per year per 100 000 in 2000 to 25.7 cases per year per 100 000 in 2010, corresponding to a reduction of 50% (95% confidence interval [CI(95)]: 45%-56%, P < .0001, adjusted for age), the bulk of the reduction occurring after 2006.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity after 5 years of anti-VEGF therapy: CATT
“VA was obtained for 647 (71%) of 914 living patients with average follow-up time 5.5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the 5-year visit, 50% of study eyes had VA 20/40 or better and 20% had VA 20/200 or worse. Mean change in VA was −3 letters from baseline and −11 letters from 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity and macular atrophy 7 years after ranibizumab: SEVEN-UP
“At a mean of 7.3 years (range, 6.3-8.5 years) after entry into ANCHOR or MARINA, 37% of study eyes met the primary end point of 20/70 or better BCVA, with 23% achieving a BCVA of 20/40 or better. Thirty-seven percent of study eyes had BCVA of 20/200 or worse.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Active exudative disease was detected by spectral-domain OCT in 68% of study eyes, and 46% were receiving ongoing ocular anti-VEGF treatments. Macular atrophy was detected by FAF in 98% of eyes, with a mean area of 9.4 mm(2); the area of atrophy correlated significantly with poor visual outcome (P<0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity after up to 7 years of treatment: Fight Retinal Blindness! registry
“After 7 years, mean VA was 2.6 letters lower than baseline for the 131 eyes still being followed; 40% had VA ≥70 (20/40) letters, and 18% had VA ≤35 letters (20/200). Of those with 20/40 VA before treatment, 40% had lost it after 7 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment was discontinued for 663 eyes (53%) within the first 5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity after 10 years of treatment: real-world meta-analysis
“Our search produced 12 observational studies encompassing 7509 eyes, with 1274 completing 10-years of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On average, there was a decline of 8.11 letters in VA after 10 years from baseline (95% CI -10.83 to -5.39, p < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Geographic atrophy after anti-VEGF therapy: CATT 5-year incidence
Macular atrophy after anti-VEGF therapy: IVAN trial and long-term follow-up
“Study eye data were available for 594 of 610 participants; 57 (9.6%) showed intralesional MA at baseline. Incident intralesional MA occurred in 24.4% by the final visit and extralesional MA in only 1.54%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Intralesional macular atrophy was present in 31.8% of the study eyes at IVAN exit (mean follow-up, 1.96 years) and 89.5% at the most recent imaging visit (mean follow-up, 6.18 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Regression models showed that the presence of ILMA and HRM was independently associated with BCVA (22 letters worse [95% confidence interval {CI}, -11.2 to -32.8; P < 0.001] and 9.8 letters worse [95% CI, -0.1 to -19.4; P = 0.047], respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fibrotic and nonfibrotic scar: CATT through 2 years
“Scar developed in 480 of 1059 eyes (45.3%) by 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fibrotic scars developed in 24.7% of eyes, and nonfibrotic scars developed in 20.6% of eyes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fibrotic scar and associated atrophy: CATT through 5 years
“Cumulative proportion of eyes with scar was 32%, 46% and 56% at year 1, 2 and 5, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 68 eyes that developed fibrotic scar at year 1, visual acuity decreased by a mean of additional 13 letters between year 1 and 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Atrophy and fibrosis as causes of long-term vision loss despite treatment
“Long-term follow-up studies have identified that the gains made in the first 2 years are not maintained in the long term” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Besides patients dropping out of treatment, evidence shows that atrophy and fibrosis are important causes of vision loss despite good early results” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Falls and fractures: population-based cohort in England
“Compared with comparators, there was an increased risk of falls in those with cataract (adjusted hazard ratio [HR], 1.36; 95% CI, 1.35-1.38), AMD (HR, 1.25; 95% CI, 1.23-1.27), and glaucoma (HR, 1.38; 95% CI, 1.35-1.41). Likewise for fractures, there were increased risks in all eye diseases, with an HR of 1.28 (95% CI, 1.27-1.30) in the cataract cohort, an HR of 1.18 (95% CI, 1.15-1.21) for AMD, and an HR of 1.31 (95% CI, 1.27-1.35) for glaucoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Falls and injuries: prospective diary study in older adults with AMD
“Overall, 74% of participants reported having either a fall or a non-fall-related injury. Fifty-four percent of participants reported a fall and 30% reported more than one fall; of the 102 falls reported, 63% resulted in an injury.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Hip fracture: Medicare beneficiaries with exudative and atrophic AMD
“In adjusted analyses, the risk of hip fractures was similar in cases that were coded with exudative AMD (odds ratio, 1.03; 95% confidence interval (CI), 0.95, 1.12) compared with cases with no AMD but was significantly higher in cases that were coded with atrophic AMD (odds ratio, 1.11; 95% CI, 1.06, 1.16).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Depression and anxiety: systematic review
“The prevalence estimates, taken from nine cross-sectional and cohort studies, ranged from 15.7%-44% for depressive symptoms and 9.6%-30.1% for anxiety symptoms in people with AMD. The seven case-control studies found that people with AMD were more likely to experience symptoms of depression compared with those without AMD, but not more likely to experience symptoms of anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Depression: recent-onset bilateral AMD
“Seventeen patients (33%) were depressed at baseline and had worse visual acuity (P =.04) and greater levels of vision-specific (P =.03) and general (P =.002) physical disability than nondepressed patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AAO Preferred Practice Pattern: falls, depression, and vision rehabilitation
PDGF-driven extracellular matrix deposition and macular scarring in neovascular AMD
“In the CATT trial, macular scarring was the most frequent anatomical correlate of impaired visual acuity, affecting every second patient at year two” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Scar tissue in nAMD has been shown to consist largely of endothelial cells, dedifferentiated RPE, fibrin, and extracellular matrix (ECM)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This notion is also supported by the fact that a longer time interval between diagnosis and start of treatment is associated with more fibrosis, and invasion of the supra-RPE space by classic CNV is associated with a six times higher hazard ratio of developing macular scarring when compared to minimally classic or occult CNV” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Neovascular age-related macular degeneration
Humanistic burden and health-related quality of life
Summary: vision-related quality of life, mental health, and treatment burden
Health utility in age-related macular degeneration depends on visual acuity in the better-seeing eye. In a time trade-off study of 80 participants, mean utility fell from 0.89 with 20/20 to 20/25 vision to 0.40 with counting fingers to light perception. In the MARINA and ANCHOR trials, a 15-letter change in best corrected visual acuity corresponded to a 4- to 6-point change in NEI VFQ-25 scores. In a five-country study, 401 participants with bilateral nAMD reported 45% worse vision-related functioning, 30% more anxiety symptoms, and 42% more depression symptoms than 471 controls, with a fall rate of 16% versus 8%. Among Medicare beneficiaries with nAMD (n = 1228), 26% reported a lot of trouble seeing or blindness compared with 5% of controls. Published prevalence of depressive symptoms in AMD ranges from 15.7% to 44%, and in a French nationwide cohort treated nAMD was associated with a 19% higher risk of both disability and mood disorders.
Treatment with repeated intravitreal injections carries its own burden. In a U.S. time-and-motion study, participants reported almost 12 hours per visit including recovery, and in a 2024 multinational survey 24.2% of participants needed 1 day or more to recover from an injection. In a UK survey of 300 participants receiving anti-VEGF therapy, 56% of participants (n = 132) reported anxiety related to treatment. In the U.S. IRIS Registry, 11.6% of 156,327 treatment-naive participants were lost to follow-up within 12 months of the last injection, and in a single urban U.S. practice the proportion was 22.2% of 9007 participants. Risk of loss to follow-up increased with age, Black race, Medicaid insurance, lower regional income, and greater distance from the clinic.
Utility values by visual acuity in the better-seeing eye: time trade-off and standard gamble
“Eighty white patients with unilateral or bilateral age-related macular degeneration in 1 or both eyes, and visual loss to a minimum of the 20/40 level in at least 1 eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean utility value for the total group with age-related macular degeneration was 0.72 (95% confidence interval [CI], 0.66-0.78) using the time trade-off method and 0.81 (95% CI, 0.76-0.86) using the standard gamble method.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using the time trade-off method correlated with the visual acuity in the better-seeing eye, the results were as follow: group 1, 0.89 (95% CI, 0.82-0.96), group 2, 0.81 (95% CI, 0.73-0.89), group 3, 0.57 (95% CI, 0.47-0.67), group 4, 0.52 (95% CI, 0.38-0.66), and group 5, 0.40 (95% CI, 0.29-0.50).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, those patients in group 1 were willing to trade 11% of their remaining lifetime in return for perfect vision in each eye, whereas those in group 5 were willing to trade 60% of their remaining lifetime in return for perfect vision in each eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
| Visual acuity group, better-seeing eye | Quoted definition |
|---|---|
| Group 1 | “1 (20/20 to 20/25)”View highlighted excerpt for this quote |
| Group 2 | “2 (20/30 to 20/ 50)”View highlighted excerpt for this quote |
| Group 3 | “3 (20/60 to 20/100)”View highlighted excerpt for this quote |
| Group 4 | “4 (20/200 to 20/400)”View highlighted excerpt for this quote |
| Group 5 | “5 (counting fingers to light perception)”View highlighted excerpt for this quote |
Utility values: visual acuity rather than underlying disease as the determinant
“No difference was found between the utility value means of the diabetic retinopathy (n = 333) and ARMD (n = 246) subgroups stratified according to visual acuity levels” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A 2-way analysis of variance demonstrated that, among the variables of ocular disease, sex, age, and visual acuity in the better-seeing eye, only visual acuity was significantly associated with utility values (P =.003).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Quality-of-life decrement by AMD severity: value-based medicine analysis
“Mild ARMD caused a 17% decrement in the quality of life of the average patient, similar to that encountered with moderate cardiac angina or symptomatic human immunodeficiency virus syndrome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Moderate ARMD caused a 32% decrease in the average patient's quality of life, similar to that associated with severe cardiac angina or a fractured hip.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Severe ARMD caused a 53% decrease in quality, more than that of dialysis, and very severe ARMD caused a 60% decrease in the average ARMD patient's quality of life” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with varying degrees of severity of ARMD were found to have quality-of-life impairment ranging from 96% to 750% greater than that estimated by treating ophthalmologists for the same condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utility instruments in AMD: HUI-3, SF-6D, EQ-5D, and time trade-off
“Two hundred nine patients were recruited with substantial loss of visual function as obtained by visual tests (mean decimal VA in the better-seeing eye: 0.2) and self-report (mean VF-14 score: 41.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (+/-SD) utilities were 0.34 +/- 0.28 for HUI-3, 0.66 +/- 0.14 for SF-6D, 0.72 +/- 0.22 for EQ-5D, and 0.64 +/- 0.31 for TTO.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ARMD is associated with a substantial impact on patients' health status, but this was not reflected in two of the generic preference-based measures used.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Utility weights in wet AMD: systematic literature review
“Of 2415 articles identified from the searches, 212 articles were reviewed in full, and 17 selected for data extraction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“HUI3 estimates were most highly correlated with VA changes, followed by TTO; no trend was observed between VA and EQ-5D or SF-6D utility weights.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The EQ-5D and SF-6D were poor indicators of the impact of VA on HRQL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NEI VFQ-25 responsiveness to visual acuity change: MARINA and ANCHOR
“According to the regression models, the difference associated with a 15-letter change was 4 to 6 points for the composite score and the three pre-specified subscales.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on MARINA and ANCHOR data, a 4- to 6-point change in NEI VFQ-25 scores represents a clinically meaningful change corresponding to a 15-letter change in BCVA.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NEI VFQ-25 change by better- or worse-seeing study eye: MARINA and ANCHOR
“We included 646 MARINA and 379 ANCHOR patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the 24-month follow-up visit, mean change in composite scores with ranibizumab seemed to be better than control for both better-seeing eyes (8.4 [95% confidence interval (CI), 5.2-11.6], 7.5 [95% CI, 3.7-11.4], and -9.4 [95% CI, -12.5 to -6.3] for the 0.3-mg, 0.5-mg, and sham groups, respectively)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bilateral nAMD versus controls: vision-related functioning, anxiety, depression, and falls (five countries)
“A cross-sectional study of 401 patients with bilateral NV-AMD and 471 elderly control subjects without AMD was conducted in 5 countries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The patients reported 45% worse vision-related functioning, 13% worse overall well-being, and 30% more anxiety and 42% more depression symptoms than controls after adjusting for covariates (all, P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The effect of NV-AMD was also observed as a doubled fall rate (16% vs 8% [P < .001]) and a quadrupled need for assistance with daily activities (29% vs 7% [P < .001]) in the patients compared with controls.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NEI VFQ-25, EQ-5D, and HADS depression versus controls: UK cohort
“Patients with NV-AMD reported substantially worse vision-related functioning and overall well-being, including higher depression scores, than controls after adjusting for age, gender and co-morbidities (adjusted mean scores: NEI-VFQ-25 overall 52.7 vs 90.7, p<0.0001; EQ-5D 0.67 vs 0.77, p = 0.0273; HADS depression 6.8 vs 4.0, p = 0.0026).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significantly more patients reported a need for assistance with daily activities compared with controls (25.3% vs 6.6%, p = 0.003).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vision impairment and functional status: Medicare Current Beneficiary Survey linked to claims
“Outcomes between community-dwelling beneficiaries with nAMD (n = 1228), DME (n = 101), or RVO (n = 251) were compared with community-dwelling beneficiaries without any VTRDs (n = 104 088), controlling for baseline demographic and clinical differences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with those without VTRDs, beneficiaries with nAMD had higher odds of diagnosed vision loss (odds ratio [OR], 5.39; 95% confidence interval, 4.06-7.16; P < .001) and difficulties with iADLs (odds ratio, 1.41; 95% confidence interval, 1.11-1.80; P = .005)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for age, sex, race/ethnicity, poverty status, comorbidities, and other relevant covariates, nAMD, DME, and RVO were not significantly associated with anxiety/depression, falls, or fractures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with nAMD continue to experience more vision impairment and worse functional status compared with a similar population of Medicare beneficiaries despite availability of therapies like antivascular endothelial growth factor to treat retinal disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disability and mood disorders after treated nAMD: French nationwide cohort
“During the study period, 1662 cases of incident nAMD were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After adjustment for age, sex, Charlson comorbidity index and number of drugs, nAMD was significantly associated with the occurrence of ADL disability (Hazard ratio (HR): 1.19, 95% confidence interval (CI): 1.08-1.30; p = 0.0002) and of mood disorders (HR: 1.19, 95%CI: 1.07-1.32; p = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treated neovascular AMD remains associated with a 19% increased risk of disability and mood disorders, while no association was detected with falls, fractures and head trauma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Depression and anxiety prevalence in AMD: systematic review
“The prevalence estimates, taken from nine cross-sectional and cohort studies, ranged from 15.7%-44% for depressive symptoms and 9.6%-30.1% for anxiety symptoms in people with AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The seven case-control studies found that people with AMD were more likely to experience symptoms of depression compared with those without AMD, but not more likely to experience symptoms of anxiety.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Depressive disorder in advanced AMD: structured clinical interview
“Participants were 151 adults aged 60 and older (mean age, 80 years) with advanced macular degeneration whose vision was 20/60 or worse in their better eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the participants, 32.5% (n = 49) met SCID-IV criteria for depressive disorder, twice the rate observed in previous studies of community-dwelling elderly.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Depression and anxiety by visual acuity severity: France, Germany, and Italy
“The prevalence of severe depression increased from 0% (BE:VA > or = 20/40+WE:VA > or = 20/200) to 7.6% (BE:VA < 20/40+WE:VA < 20/200), whereas anxiety was unrelated to VA loss.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, total depression scores were strongly associated with VA severity (P = 0.006), but not total anxiety scores (P = 0.840).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incident depression after AMD diagnosis: Korean nationwide cohort
“A total of 3 599 589 individuals older than 50 years participated in the Korean National Health Screening Program in 2009.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with previous diagnoses of AMD showed a greater risk of new-onset depression, with a hazard ratio of 1.15 (95% CI, 1.13-1.17) compared with the control group in the fully adjusted model.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with AMD and accompanying VD showed a further increased risk of depression, with a hazard ratio of 1.23 (95% CI, 1.16-1.30).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related anxiety and clinical depression during anti-VEGF therapy: UK
“Three hundred patients with wAMD receiving anti-VEGF treatment and 100 patient carers were recruited.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Qualitative data showed that 56% of patients (n = 132) reported anxiety related to anti-VEGF treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The main sources of anxiety were fear of going blind owing to intravitreal injections and concerns about treatment effectiveness, rather than around pain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From validated questionnaires, 17% of patients (n = 52) showed clinical levels of anxiety and 12% (n = 36) showed clinical levels of depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient-reported outcomes and mental health in routine anti-VEGF care: systematic review
“Of 856 records identified, 63 met inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Depression or depressive symptoms were reported in up to 42% of patients with nAMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, seven reported a statistically significant improvement at the earliest time point measured (Month 3-12) and approximately 50% reported sustained QoL benefits at 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time burden per visit: U.S. time-and-motion study
“Fifty-six physicians provided data for 221 patients with neovascular AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An average patient visit for neovascular AMD was 90 minutes (range: 13 minutes to >4 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported an average time per visit of almost 12 hours, including preappointment preparation (16 minutes), travel (66 minutes), waiting time (37 minutes), treatment time (43 minutes), and postappointment recovery (9 hours).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment barriers, recovery time, and work absenteeism: multinational patient survey including the United States
“This multinational, non-interventional, quantitative, cross-sectional, observational survey assessed treatment barriers/burden, patient-reported visual functioning, and treatment satisfaction in DME and nAMD patients in the USA, the UK, Canada, France, Italy, and Spain.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The survey was completed by 183 DME and 391 nAMD patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients reported ≥1 barrier (66.1% DME, 49.2% nAMD patients) related to treatment (35.0%), clinic (32.6%), and COVID-19 (21.1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nearly one-quarter (24.2%) of patients needed ≥1 day to recover from intravitreal injections; most reported ≥30 min of travel time (73.7%) and clinic wait time (54.2%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient and ophthalmologist perceptions of injection burden: U.S. survey
“In June 2024 a survey of 101 patients (50 with DME and 51 with nAMD) and 100 ophthalmologists who treat these conditions completed surveys.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-six percent and 86% of patients with DME and nAMD, respectively, reported receiving intravitreal injections at least once every 8 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eighty-two percent required a caregiver and/or public transportation to get to their appointments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“They overestimated the extent to which patients became less nervous with subsequent injections after the first (3.40 vs 2.94; P < 0.01) and underestimated their difficulty of getting to appointments (2.30 vs 2.64; P < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pre-injection anxiety, stress, and discomfort: Norway survey
“In total, 130 patients responded to the survey.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of patients reported to receive nine or more injections per year (48.8%), and many patients needed caregiver support for every treatment appointment (37.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported to be anxious one day (25.4%), two days (8.5%), one week (10.8%) or more than one week (3.1%) prior to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The week before the treatment, 33.1% of patients reported to be stressed and 15.4% struggled to sleep.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Time per treatment visit and caregiver assistance: Sweden
“The study included 93 patients with an average age of 79.9 years, 68% were women.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On average, patients had to spend 2.7 h (2.4-2.9: 95% CI) per treatment and a caregiver assisted the patient in 58% of cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Psychosocial and practical burden of repeated injections: qualitative study
“Patients recognised the importance of treatment to preserve eyesight, yet experienced significant psychosocial and practical burden from the treatment schedule.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Important issues included treatment-related anxiety, financial considerations and transport burden placed on relatives or carers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients prioritised treatment, often sacrificing family, travel and social commitments owing to a fear of losing eyesight if treatment was not received.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Challenges in nAMD management: global survey of patients, providers, and staff
“There were 6425 responses; 4558 patients with neovascular age-related macular degeneration, 659 providers, and 1208 clinic staff.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Challenges identified included concern about patient burden to family/friends, high frequency of treatment, difficulties in traveling to appointments, long waiting times, and insufficient comprehension of neovascular age-related macular degeneration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obstacles to treatment and missed clinic visits: nine-country patient survey
“Most patients (65.4%; n=595/910) and caregivers (77.0%; n=685/890) reported a number of obstacles in managing wAMD (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For patients, the main barrier was the treatment itself (34.8%; n=317/910)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Other barriers included treatment costs (27.8%; n=253/910) and finding the right treatment option (27.4%; n=249/910)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the 15.7% (n=143/910) of patients who missed a clinic appointment, the main obstacles were that the caregiver was unable to take them to the appointment (25.9%; n=37/143), fear about receiving an injection (21.0%; n=30/143), and patient illness (reason not stated) (18.9%; n=27/143).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Loss to follow-up and nonpersistence: U.S. IRIS Registry
“One hundred fifty-six thousand three hundred twenty-seven treatment-naive patients with neovascular AMD who subsequently were treated with anti-VEGF therapy from 2013 through 2015 and followed up through 2019.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For neovascular AMD, 11.6% of patients (95% CI, 11.4%-11.7%) were LTFU, and 88.4% of patients were followed up within 12 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Odds of being LTFU were higher for patients with Medicaid insurance (OR, 1.27; 95% CI, 1.01-1.60; P = 0.04) and lower for patients with Medicare Fee-For-Service insurance (OR, 0.69; 95% CI, 0.64-0.74; P < 0.001) than for patients with private insurance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, 14.3% (95% CI, 14.1-14.4) of patients were nonpersistent, and 85.7% of patients underwent follow-up within 6 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Loss to follow-up by age, income, and distance: U.S. urban retina practice
“Among the 9007 patients (mean [SD] age, 81.2 [8.8] years; 5917 [65.7%] female; 7905 [87.8%] white), 2003 (22.2%) were LTFU.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Odds of LTFU were greater among patients with regional adjusted gross income of $50 000 or less (OR, 1.52; 95% CI, 1.30-1.79; P < .001), $51 000 to $75 000 (OR, 1.35; 95% CI, 1.17-1.56; P < .001), and $76 000 to $100 000 (OR, 1.28; 95% CI, 1.08-1.50; P = .004) compared with patients with incomes greater than $100 000.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Odds of LTFU for patients living 21 to 30 miles (OR, 1.33; 95% CI, 1.05-1.69; P = .02) and more than 30 miles (OR, 1.55; 95% CI, 1.28-1.88; P < .001) from clinic were greater compared with patients who lived 10 miles or less from the clinic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nonadherence and nonpersistence: mixed-methods systematic review
“Of the 1284 abstract results screened, 124 articles were assessed in full and 37 studies met the inclusion criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonpersistence occurred early, with up to 50% of patients stopping treatment by 24 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High rates of nonadherence were similarly reported, occurring in 32% to 95% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual outcomes after loss to follow-up of more than 6 months
“A total of 169 patients were classified into 43 in the long-term LTFU group, 57 in the short-term LTFU group, and 69 in the CFU group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The final visual acuity was significantly lower in the long-term LTFU group (1.12 ± 0.79) compared with the short-term LTFU group (0.65 ± 0.62) and the CFU group (0.65 ± 0.56) (P < 0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Maintenance of driving vision over 4 years by first-year injection count
“In year 1, the nAMD and DME cohorts gained 8.5 and 9.5 ETDRS letters, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Between years 1 and 4, patients with nAMD and DME lost 6.6 and 2.7 ETDRS letters, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The probability of maintaining driving vision over 4 years was 56% (nAMD) and 72% (DME); among patients who received 1 to 5, 6 to 7, and ≥ 8 anti-VEGF injections in year 1, corresponding probabilities were 50%, 56%, and 65% (nAMD; P < 0.001)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Injection frequency and duration of treatment before loss to follow-up: U.S. IRIS Registry
“Among patients who were LTFU, the average number of anti-VEGF injections was 14 (average frequency, every 2.1 months), whereas the average number of anti-VEGF injections for those not LTFU during the same period was 12 (average frequency, every 2.5 months; Table 4).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients who were LTFU, the average time from the first intravitreal injection to the last visit was 2.4 years and was 4.4 years for patients not LTFU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity at the last visit among nonpersistent participants: U.S. IRIS Registry
“Compared with patients without nonpersistence during the same follow-up period, a lower percentage of patients with nonpersistence showed VA of 20/40 or better (35% vs. 43%; P < 0.001) at the last visit (Table 5) in the treated eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared with patients without nonpersistence during the same follow-up period, a higher percentage of patients with nonpersistence lost > 5 ETDRS letters (40% vs. 36%; P < 0.001; Table 5) in the treated eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Return to care after loss to follow-up or nonpersistence: U.S. IRIS Registry
“Twelve percent of patients who were LTFU did later undergo follow-up (defined as after the first year and within 4 years of the last anti-VEGF intravitreal injection).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-eight percent of patients who were nonpersistent did later undergo follow-up (defined as after the first 6 months and within 4 years of the last anti-VEGF intravitreal injection).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Travel time, clinic waiting time, and appointment duration of 1 hour or more
“Overall, 41.3% (n = 237) reported having ≥1 h of travel time to their appointment and 29.4% (n = 169) had ≥1 h of waiting time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately equal proportions of patients experienced a combined (injection and examination) appointment duration of <1 h (29.4%; n = 169) and ≥1 h (32.9%; n = 198).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Impairment in activities of daily living and work absenteeism attributed to treatment
“Nearly half of patients (n = 258, 44.9%) reported some level of impairment in their ADL due to treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among working patients (n = 42 DME; n = 24 nAMD), 62.1% experienced some level of absenteeism at work.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Elements of treatment burden associated with lower treatment satisfaction
“Treatment satisfaction scores were worse with higher time-related impacts of treatment (both nAMD and DME), higher impacts on finances and daily life (nAMD), and negative impacts on employment and lower expectations for treatment effectiveness (DME).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, patients reporting a higher treatment burden (e.g., longer wait times) had worse treatment satisfaction scores.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were generally satisfied with their current treatment (MacTSQ, mean total score = 59.2, SD = 9.6; RetTSQ, mean total score = 61.3, SD = 12.8).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visit length and post-injection recovery reported by U.S. participants
“More than one-third (36%, 27 of 75) of patients reported that their most recent visit took 90 minutes or more, and 79% (59 of 75) reported spending at least 3 hours recovering following injections.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average age was 79 years (range 55–98 years) and 89% (67 of 75) of patients had a concomitant medical condition.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Monthly injection and monitoring visits as the stated driver of extended-interval development
“The risk of rare but serious adverse events resulting from the intravitreal procedure, together with the significant burden of making monthly visits to their retinal specialist, have led to extensive efforts to decrease injection and monitoring frequency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By halving the need for monthly visits, the every-2-month regimen of aflibercept may markedly decrease the treatment burden experienced by patients and their families.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Strength of and reasons for patient preference for continuous delivery over injections
“A fairly or very strong preference for the PDS was expressed by 88% (22/25) of respondents (Fig 8), with fewer treatments (72% [18/25]) and less discomfort (64% [16/25]) being the most frequently cited reasons for preference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Patient preference for continuous delivery over monthly injections in Archway
“At week 40, 218 of 234 PDS-treated patients (93.2%) preferred ranibizumab as delivered via the PDS compared with intravitreal injection, as assessed by the PDS Patient Preference Questionnaire; 3 patients (1.3%) preferred intravitreal injections and 13 patients (5.6%) reported no preference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Summary: Medicare spending, per-patient costs, and real-world utilization
Anti-VEGF agents for macular degeneration account for a large share of Medicare Part B drug spending. In 2024, fee-for-service Medicare spent $3.0 billion on Eylea (including Eylea HD) for 329,500 users and $1.9 billion on Vabysmo for 173,300 users; Eylea ranked second and Vabysmo sixth among all Part B products, with average spending per user of $9,200 and $11,100. Across 2014 to 2023, Medicare fee-for-service beneficiaries received 36,398,293 intravitreal anti-VEGF injections, and aflibercept use increased from 618,796 injections in 2014 to 1,713,729 in 2023.
In U.S. commercial claims (6,076 participants), mean annual all-cause cost was $24,520 per patient, and nAMD-related outpatient visit costs were $8,658 for active choroidal neovascularization compared with $2,406 for inactive disease. A prevalence-based model estimated per-annum costs of $55,752 per person with nAMD in the United States when productivity and well-being losses are included. Vision loss of all causes cost the United States an estimated $134.2 billion in 2017.
Real-world injection counts are lower than in registration trials: a mean of 7.3 injections in year 1 in the Vestrum database (49,485 eyes), 6.0 in U.S. electronic health records, and 7.2 in year 1 falling to 4.2 to 4.6 per year in years 3 to 6 in the IRIS Registry. In these data, visual acuity outcomes increased with injection count, and in the IRIS Registry mean visual acuity was 4.6 letters below baseline after 6 years.
Medicare Part B spending on macular degeneration drugs, 2024
Medicare Part B spending on macular degeneration drugs, 2023
Medicare anti-VEGF injection volume and reimbursement per injection, 2014 to 2023
“From 2014 to 2023, a total of 36 398 293 intravitreal anti-VEGF injections were administered to Medicare beneficiaries.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Aflibercept use increased significantly (618 796 injections in 2014 vs. 1 713 729 in 2023; τ = 0.91; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Faricimab demonstrated rapid early uptake after its introduction in 2022 (65 052-556 512 injections).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Standardized Medicare reimbursement per injection declined significantly for ranibizumab ($1234.35-$724.74; τ = -1.00; P < 0.001) and aflibercept ($1527.37-$1379.54; τ = -0.82; P = .001), remained stable for brolucizumab, and increased for bevacizumab ($46.76-$300.73; τ = 0.69; P < 0.01).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
On-label versus off-label anti-VEGF use and Part B spending by community, 2013 to 2023
“From 2013-2023, 5,178 providers billed Part B for 34.5 million anti-VEGF injections.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Equalizing anti-VEGF mix to that of the highest-poverty quartile would have resulted in approximately $4.2 billion lower spending.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Anti-VEGF injection trends in Medicare Part B, 2013 to 2021
“Among 26 602 816 total injections performed from 2013 to 2021, relative usage of aflibercept increased by 158.3%, while relative usage decreased by 27.5% for ranibizumab and 49.6% for bevacizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Step therapy has not significantly increased bevacizumab usage on an aggregate level.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare Part B spending per beneficiary on ranibizumab and aflibercept, 2011 to 2015
“During this 5-year period, associated Medicare drug costs averaged $1.3 billion annually.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Annual Medicare drug expenditure for aflibercept was $1.4 billion on average.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On average, Medicare spent $9719 and $9934 annually on each beneficiary receiving ranibizumab and aflibercept injections, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ranibizumab and aflibercept costs account for 12% of the Medicare Part B budget annually.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Estimated Medicare and patient savings from bevacizumab use, 2008 to 2015
Manufacturer payments to ophthalmologists and Medicare Part B spending, 2013 to 2019
“Ophthalmologists who accepted manufacturer payments were significantly less likely to prescribe bevacizumab (28.0% [95% CI, 24.6%-42.5%] of patients) compared with those who did not accept manufacturer payments (45.8% [95% CI, 44.5%-47.1%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Had ophthalmologists who accepted manufacturer payments prescribed ARMD drugs as those who did not accept payments, Medicare spending on these treatments would have been $642 779 703.08 lower from 2013 to 2019, a 2.0% savings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Direct costs and resource use by disease activity: U.S. commercial claims
“A total of 6,076 patients with nAMD were identified for the prevalent cohort; 60.1%, 17.2%, and 5.9% had active CNV, inactive CNV, and inactive scar disease stage at index, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The nAMD-related outpatient visit costs were roughly 4 and roughly 7 times higher, respectively, for the active CNV group ($8,658 [SD = $11,612]) compared with the inactive CNV ($2,406 [SD = $5,510]) and inactive scar ($1,198 [SD = $3,035]) groups (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“About 10% of prevalent patients had a fall/fracture claim over 12 months of follow-up.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 3,623 prevalent patients (59.6%) were eligible for the anti-VEGF treatment patterns analysis (mean [SD] duration of therapy = 7.7 [4.5] months; mean [SD] number of injections = 6.0 [3.7]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) annual total all-cause cost for the prevalent cohort was $24,520 ($43,950) with outpatient costs as the largest cost component (63.5%; Supplementary Figure 2 (577KB, pdf) , available in online article).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Multivariate GLM results revealed an increasing trend in costs with increasing anti-VEGF injection frequency; there were 73% higher costs for patients with 4-6 injections to 342% higher costs for those with 10 or more injections compared with those with 1-3 injections over 1 year of follow-up (P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Outpatient visit type, prevalent cohort | All patients | Active CNV | Inactive CNV | Inactive scar |
|---|---|---|---|---|
| All-cause visits, mean (SD) | “30.6 (26.4)”View highlighted excerpt for this quote | “31.0 (25.5)”View highlighted excerpt for this quote | “27.5 (25.3)”View highlighted excerpt for this quote | “27.1 (25.9)”View highlighted excerpt for this quote |
| nAMD-related visits, mean (SD) | “6.6 (4.8)”View highlighted excerpt for this quote | “7.7 (4.6)”View highlighted excerpt for this quote | “4.1 (3.5)”View highlighted excerpt for this quote | “2.9 (2.9)”View highlighted excerpt for this quote |
| Anti-VEGF-related visits, mean (SD) | “3.9 (4.2)”View highlighted excerpt for this quote | “5.1 (4.2)”View highlighted excerpt for this quote | “1.3 (2.5)”View highlighted excerpt for this quote | “0.5 (1.6)”View highlighted excerpt for this quote |
Real-world injection frequency and per-patient cost: ranibizumab and aflibercept in U.S. claims
“After adjusting for patient demographics and clinical characteristics, per-patient injection frequency and cost were not significantly different between treatment-naive patients with nAMD who received ranibizumab versus aflibercept over 12 months (5.62 vs. 5.54; P = 0.52, and $11,351 vs. $10,702; P = 0.06, respectively) and 24 months (7.86 vs. 8.37; P = 0.16, and $16,286 vs. $16,666; P = 0.69, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients received fewer injections than any FDA-indicated dosing schedule, suggesting potential undertreatment that may result in suboptimal vision outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare Part B payments in the first year after nAMD diagnosis, 1994 to 2006 cohorts
“Overall yearly Part B payments per beneficiary increased significantly from $3,567 for the 1994 to $5,991 for the 2006 cohort (p<0.01) in constant 2008 dollars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Payments for eye care alone doubled from $1,504 for the 1994 cohort to $3,263 for the 2006 cohort (p<0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most of the increase in payments for eye care in 2006 reflected payments for anti-VEGF injections, which were $1,609 over 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Societal cost of late-stage AMD in the United States, Germany, and Bulgaria
“Estimated per-annum total costs attributable to late-stage AMD were €449.5 million ($512.5 million) in Bulgaria, €7.6 billion ($8.6 billion) in Germany, and €43.2 billion ($49.4 billion) in the US.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across all countries, 10% to 13% of the total cost incurred was attributed to direct medical costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Germany and Bulgaria, the biggest contributor to the total economic burden was reduced well-being (67% and 76%, respectively), whereas in the US, loss of productivity (42%) was the biggest contributor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In nAMD, the loss of productivity accounted for 46% of the total cost, and in GA, it accounted for 36%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The financial costs incurred due to nAMD amounted to €17.2 billion ($19.7 billion) and totaled €13.4 billion ($15.3 billion) for GA (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Per-annum individual costs incurred due to nAMD and GA were estimated at €48 895 ($55 752) and €39 250 ($44 755), respectively (Table 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden of vision loss and blindness in the United States (2017)
“We estimated an economic burden of VL of $134.2 billion: $98.7 billion in direct costs and $35.5 billion in indirect costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The largest burden components were NH ($41.8 billion), other medical care services ($30.9 billion), and reduced labor force participation ($16.2 billion), all of which accounted for 66% of the total.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Those with VL incurred $16 838 per year in incremental burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Informal care was the largest burden component for people 0 to 18 years of age, reduced labor force participation was the largest burden component for people 19 to 64 years of age, and NH costs were the largest burden component for people 65 years of age or older.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Lost gross domestic product attributable to AMD in the United States
Work productivity loss in AMD: meta-analysis
“Seven studies consisting of 3,060,864 subjects from 5 different countries were included in this systematic review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean wages lost due to impaired work productivity ranged from $1,395 to $55,180.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean unemployment rate attributed to AMD ranged from 5.50% to 77.00%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modeled direct and indirect costs of extended-interval agents: aflibercept 8 mg versus faricimab (United States)
“Direct costs were estimated based on modeled mean injection numbers and 2025 wholesale acquisition costs per injection (aflibercept 8 mg: 2677.50 USD; faricimab: 2289.65 USD) plus medical monitoring costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over a 3-year time horizon, the mean number of injections was lower with aflibercept 8 mg versus faricimab for nAMD (12.25 vs. 14.80 injections) and DME (11.80 vs. 15.65 injections).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Total costs (direct and indirect) associated with aflibercept 8 mg were 1978.74 USD lower than faricimab for nAMD and 6032.90 USD lower than faricimab for DME.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world injection frequency and visual acuity: Vestrum Health Retina Database (United States)
“In this analysis, 49 485 eyes were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 1 year, after a mean of 7.3 anti-VEGF injections, there was a mean gain of 1 letter (0.95 letter; 95% confidence interval [CI] for change in VA, +0.77 to +1.13 letter; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was a linear relationship between mean letters gained and mean number of injections, between 4 and 10 injections over 1 year, with 4 or fewer or 10 or more injections associated with loss of vision or a plateau, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Real-world nAMD patients receive fewer anti-VEGF injections and experience worse visual outcomes compared with patients receiving fixed, frequent therapy in randomized controlled trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Visits, injections, and visual acuity in U.S. electronic health records
“Over the first 12 months, patients made a mean of 8.1 (range, 1-39) ophthalmologist visits, received a mean of 6.0 (range, 1-27) anti-VEGF injections, and underwent 7.2 OCT and 5.3 FA examinations per study eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean change from baseline VA at 12 months increased linearly with cumulative anti-VEGF injection count: +1.79 versus -0.95 approximate ETDRS letters for eyes receiving 7 or more injections versus fewer than 7 injections.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Six-year injection frequency, discontinuation, and visual acuity: U.S. IRIS Registry
“A cohort of 254 655 eyes (226 767 patients) with first anti-VEGF injection and at least 2 years of follow-up; 160 423 eyes had visual acuity (VA) data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a mean VA increase of 3.0 ETDRS letters at year 1, annual decreases led to a net loss from baseline of 4.6 letters after 6 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From a mean of 7.2 in year 1 and 5.6 in year 2, mean injections plateaued between 4.2 to 4.6 in years 3 through 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment was discontinued in 38.8% of eyes and switched in 32.3%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the patients, 58.5% lost ≥ 10 letters VA at least once during follow-up, with 14.5% of patients experiencing sustained poor vision after a median of 3.4 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-year injection counts by agent: U.S. IRIS Registry
“Of 13 859 patients, 6723 received bevacizumab, 2749 received ranibizumab, and 4387 received aflibercept only for 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean number of injections (standard deviation) at 1 year was higher in the ranibizumab (6.4 [±2.4]) and aflibercept groups (6.2 [±2.4]) compared to bevacizumab group (5.9 [±2.4]; P < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world injection frequency and visual acuity: eight-country AURA study
“2227 patients who received ≥1 anti-VEGF injection with a baseline visual acuity assessment and ≥1 postbaseline visual acuity assessment for the treated eye were evaluated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Causes of undertreatment in routine practice: literature review
“In real-world practice, patients are usually undertreated, accounting for the VA decline over time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reasons for undertreatment include the burden of injections and monitoring visits imposed on patients/caregivers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Blindness incidence and healthcare system impact after anti-VEGF introduction: systematic review
“Population-based analyses reported reduction in incidence among the general population of 47% (9.1 cases/100,000 in 2006 to 4.8 cases/100,000 in 2011).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The introduction of anti-VEGF led to increased overall treatment costs due to replacement of existing less frequently administered treatments (e.g. photodynamic therapy) and increased number of patients treated (prior to anti-VEGF, only ~ 20% of patients were eligible for treatment).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Societal cost of bilateral nAMD: five-country observational study (2005 euros)
“In the previous 12 months, 12-22% of patients fell, and half of these patients required medical treatments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The average annual societal cost per bilateral NV-AMD patient treated was estimated to be euro 7879 in Canada, euro 7349 in France, euro 12 445 in Germany, euro 5732 in Spain and euro 5300 in the UK, and direct vision-related medical costs accounted for 23-63% of the total cost.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual healthcare utilization costs versus controls: UK cohort
Patient-centered incremental costs, including out-of-pocket costs: South Korea
“We identified 931 patients with exudative AMD and matched 783 (84.1%) with 2918 patients with nonexudative AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the exponential conditional model, the total medical, reimbursement, nonreimbursement, and out-of-pocket incremental costs were estimated at US $3426, US $3130, US $366, and US $561, respectively, in the first year and US $1829, US $1461, US $373, and US $507, respectively, in the second year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vision impairment due to AMD: Global Burden of Disease 2021
“Globally, the number of individuals with vision impairment due to AMD more than doubled, rising from 3·64 million (95% uncertainty inverval [UI] 3·04-4·35) in 1990 to 8·06 million (6·71-9·82) in 2021.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, DALYs increased by 91% over the same period, from 0·30 million (95% UI 0·21-0·42) to 0·58 million (0·40-0·80).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Five-year trend in first-year injection numbers by initial anti-VEGF agent, United States
“In 2012, there were 6.7 yearly injections, 7.3 yearly injections, and 7.2 yearly injections on average in the groups initially treated with bevacizumab, aflibercept, and ranibizumab, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“By 2016, the mean number of yearly injections in the groups initially treated with bevacizumab and ranibizumab had increased by approximately 1, to 7.8 and 8.0 yearly injections, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Injection visits and dosing schedules in routine care: multinational survey including the United States
“Within 12 months, nAMD patients attended more visits where anti-VEGF injections were administered (nAMD: mean = 7.74, SD = 3.63; DME: mean = 6.54, SD = 3.40).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One-third of DME (33.9%) and one-quarter of nAMD patients (25.8%) were on a fixed treatment schedule, with 73.6% (n = 120 of 163) receiving injections every ≤8 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“About one-third of nAMD (38.1%) and one-quarter of DME (26.8%) patients were on a treat-and-extend (T&E) regimen, with 69.7% (n = 138 of 198) receiving injections every ≤8 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retina practice staff time devoted to neovascular AMD management: U.S. time-and-motion study
“The results of the retina specialist survey showed that on average, 23 staff members were involved in the management of neovascular AMD patients, including the receptionist, the office manager, the billing manager, technicians, and other physicians or staff (Table).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The management of patients with neovascular AMD accounted for an average of 20% of the staff’s time per work week: most technicians (68%) spent more than 20% of their time, one-quarter of office managers spent more than 10% of their time, and more than one-third (37%) of billing managers spent more than 20% of their time managing patients with neovascular AMD (Figure 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Although these preparatory steps were typically performed concurrently, the average total staff time spent on all preparation steps was 43 minutes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
State-level variation in Medicare anti-VEGF injection rates, 2023
“West Virginia had the lowest overall injection rate at 5723/100 000 Medicare beneficiaries, whereas Alaska had the highest rate at 180 838/ 100 000, representing a 31.6-fold difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For aflibercept, Alaska recorded the highest injection rate at 68 241/100 000, whereas Hawaii had the lowest at 2602/100 000, resulting in a 26.2-fold difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Faricimab utilization ranged from 207/100 000 in Vermont to 10 247/100 000 in Nebraska, a 49.4-fold difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Bevacizumab use was the highest in Alaska at 93 497/100 000 and lowest in West Virginia at 630/100 000, representing a 148.3-fold difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Total Medicare anti-VEGF expenditure and per-beneficiary utilization, 2014 to 2023
“From an economic perspective, total Medicare expenditures for anti-VEGF therapy rose from approximately $2.5 billion USD in 2014 to $3.7 billion USD in 2023, despite declining reimbursement per injection for aflibercept and ranibizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This increase was primarily driven by rising injection volumes and the introduction of newer branded agents (faricimab and brolucizumab).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“To summarize per-100 000-beneficiary utilization, aflibercept increased from 1864/100 000 to 5997/100 000 beneficiaries (221% rise)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Faricimab increased from 219/100 000 to 1947/100 000 between 2022 and 2023 (789% rise), whereas brolucizumab declined from 142 to 18 per 100 000 (87% decline).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Neovascular age-related macular degeneration on families
Summary: caregiver time, lost work, and transport
Most people receiving anti-VEGF therapy for nAMD rely on an informal caregiver to attend appointments. In a nine-country survey, 82.1% of 910 participants received caregiver support and 56.7% were usually taken to appointments by a caregiver. In a U.S. time-and-motion study, participants reported that caregivers took time away from work (22%) and personal activities (28%) to provide transport. In a 2024 multinational survey including U.S. caregivers, 70.5% of working caregivers (n = 44) reported absenteeism due to treatment or monitoring appointments. In a UK survey of 250 caregivers, 24.8% took time off work and 70% spent at least half a day on each clinic visit. An Australian study estimated caregiver time accompanying the patient at 6.2 hours per month and an annual caregiver cost of AU$5,333.58. A U.S. economic model applied an indirect cost of $289.98 per injection for patient and caregiver time and travel. In a 2006 U.S. survey, annual caregiving costs ranged from $225 to $47,086 depending on visual acuity.
Caregiver time away from work for transport: U.S. time-and-motion study
“A survey was administered to 75 neovascular AMD patients aged ≥50 years who received ≥1 anti-VEGF injection in the past 6 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Telephone interviews were conducted with 13 neovascular AMD patient caregivers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients stated that caregivers took time away from work (22%) and personal activities (28%) to provide transportation to appointments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiving use and cost by visual acuity: U.S. survey
“Of 803 respondents, 56% were male, and the mean age was 73 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Use of paid and unpaid help significantly increased as visual acuity decreased.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Using a national average for caregiver time, annual costs for caregiving ranged from 225 to 47,086 US dollar depending on visual acuity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver time and work absenteeism: multinational caregiver survey including the United States
“Caregivers for patients with DME (n = 30) and nAMD (n = 95) completed surveys.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean ± SD length of time as a caregiver was 9.1 ± 10.0 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Caregivers estimated they provided support for 4.2 ± 2.9 days/week and 6.0 ± 7.1 h/day on average.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nearly half of caregivers (45.6%) reported some impairment in daily activities, and more than two-thirds (70.5%) of working caregivers (n = 44) reported work absenteeism due to anti-VEGF treatment/monitoring appointments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden, time off work, and loss of income: UK
“This is a cross-sectional questionnaire survey of 250 matched patient caregiver dyads across three large ophthalmic treatment centres in United Kingdom.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean CRA score was 3.2±0.5, similar to the score reported by caregivers for atrial fibrillation who require regular hospital appointments for monitoring their thromboprophylaxis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ranibizumab therapy for nAMD is associated with significant caregiver burden. Both disease impact and treatment frequency contributed to the overall burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common eye-related care activity undertaken was accompanying patients for their eye clinic appointments, with 70.8% carers having attended ≥10 appointments over the last year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On an average, the caregivers reported that 70% spent at least half a day and 43.6% spent most of the day assisting their patient with their clinic visit every 4–6 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“24.8% of caregivers required time off work to support patients with their eye treatment, and 10% of them reported that this led to a loss of income.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver roles and attendance at appointments: nine-country patient and caregiver survey
“A total of 910 patients with wAMD and 890 caregivers completed the questionnaire.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of patients (82.1%; n=747/910) received support from a caregiver.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only 6.5% (n=58/890) were professional (paid) caregivers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most caregivers always attended appointments (60.1%; n=535/890) and were involved in discussions about the treatment plan (83.3%; n=555/666; Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients (56.7%; n=516/910) were usually taken to the appointment by a caregiver; however, 20.4% (n=186/910) went by public transport, 12.4% (n=113/910) drove themselves, 8.1% (n=74/910) used a taxi, and 2.3% (n=21/910) were taken by an ambulance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver time and costs: Australia (Australian dollars)
“The caregivers reported the time they spent accompanying the patient to their medical appointments specifically for intravitreal injections took an average of 6.2±1.1 hours per month, which equates to a loss of $262.45±$46.60 in income based on the national average hourly wage.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several caregivers indicated indirect costs due to lost productivity in the workplace, having to take considerable time off work in order to bring the patient in for monthly appointments and injections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Cost or time item | Mean ± SD |
|---|---|
| Number of visits per year | “10.4±0.8”View highlighted excerpt for this quote |
| Travel and parking costs, AU$ | “64.80±79.70”View highlighted excerpt for this quote |
| Travel time per visit, hours | “2.4±1.6”View highlighted excerpt for this quote |
| Caregiver time spent accompanying patient to appointment, hours | “6.2±1.1”View highlighted excerpt for this quote |
| Hours per week needing assistance | “4.3±3.2”View highlighted excerpt for this quote |
| Annual mean cost of caregivers, AU$ | “5,333.58±2,184.20”View highlighted excerpt for this quote |
Caregiver time off work per treatment visit: Sweden
“Caregivers spent on average 2.6 h (2.5-2.8: 95% CI) per visit, and 19% needed to take time off work.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The majority (91%) of patients did not experience any transportation problems associated with treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Indirect cost per injection for patients and caregivers: U.S. economic model
“Indirect costs per injection for patients and carers were calculated using multiple parameters, including caregiver time taken for an injection appointment [31], the average US wage per working hour [32], reduction in hourly wage for nonworking people’s time [33], hours of lost productivity for a patient due to the injection and appointment [34], percentage of carers’ time taken from activities [34], percentage of patients who require a caregiver [34], the average distance, in miles, traveled to get to an appointment [34, 35], and cost per mile traveled [36], for an indirect total cost of 289.98 USD per injection for patient and carer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Indirect costs represent a relatively small proportion of the overall costs compared with the drug costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver share of productivity losses: late-stage AMD in the United States
“Parameters included patient job loss, patient job reduction, caregiver job reduction due to caregiving responsibilities, caregiver job reduction due to providing transport to eye health care appointments, and caregiver loss of leisure time due to providing transport.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In nAMD, 99% of the total cost attributed to the loss of productivity was due to the impact on patients, with caregivers contributing to the remaining 1% of the cost.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospital appointments as a driver of caregiver burden: systematic review
“The need to attend hospital appointments was identified in various studies as an important contributor to caregiver burden (Gohil et al., 2015; Varano et al., 2015; Spooner et al., 2018).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately two‐thirds of patients required an accompanying person for travel to/from the clinic (Droege et al., 2013; Varano et al., 2015; Muller et al., 2017).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In another (n = 100 caregivers), approximately 75% of caregivers reported little or no burden associated with supporting patients with nAMD, as evaluated on the Burden Assessment Scale (Senra et al., 2017).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver perceptions of the impact of caring: survey of 643 caregivers
“A cross-sectional, self-administered survey of 643 caregivers of people with neovascular AMD, comprising 27 closed-response questions and 2 open ended questions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Very few seek or receive respite and this added burden can have a negative impact upon the relationship between caregiver and care recipient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Who transports participants to injection visits, and out-of-pocket transport costs
“The majority of patients (72%, 54 of 75) were driven to their appointment by a caregiver.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Their caregiver was a spouse or partner (65%, 35 of 54), an adult child or grandchild (22%, 12 of 54), a friend (7%, 4 of 54), or another person (6%, 3 of 54).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Few patients experienced direct out-of-pocket transportation costs. Eighty-nine percent (67 of 75) reported that they did not pay any transportation costs for their latest clinic visit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Household income of U.S. participants receiving anti-VEGF injections
“The average income was $40 000. The majority of patients (62%, 46 of 75) reported an income of less than or equal to $50 000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Seventeen percent (13 of 75) reported an income between $50 001 and $75 000 while 10% (8 of 75) had an income greater than $75 000.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
Summary: imaging for diagnosis and treatment monitoring
Diagnosis and retreatment decisions in nAMD rely on retinal imaging, principally optical coherence tomography (OCT), with fluorescein angiography used mainly at diagnosis. A 2025 U.S. model priced an initial visit with office visit, OCT, and fluorescein angiography at $534.15 and each subsequent office visit with OCT at $184.58. In U.S. electronic health records, eyes underwent a mean of 7.2 OCT and 5.3 fluorescein angiography examinations in the first 12 months of treatment, and in commercial claims 88.1% of participants had at least one OCT visit per year (mean 4.5 visits). Among Medicare retina specialists, OCT increased from 61.5% of imaging in 2012 to 70.5% in 2016 while fluorescein angiography fell from 20.9% to 15.1%. OCT-guided as-needed and treat-and-extend dosing was estimated to have saved the U.S. government $9.0 billion and patients $2.2 billion from 2008 to 2015, net of about $0.8 billion in OCT imaging costs. In UK economic evaluations, SD-OCT monitoring of the fellow eye had lower lifetime costs than other monitoring tests, and strategies using OCT alone for diagnosis or monitoring were unlikely to be cost-effective.
Cost of monitoring visits with OCT and fluorescein angiography: U.S. model inputs (2025)
“The direct medical monitoring costs (2025, in USD) [29, 30] included office visits, fluorescein angiography, and optical coherence tomography (OCT) (Table S1 in the electronic supplementary material).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Monitoring cost for initial visit in year 1 = (initial office visit + OCT + fluorescein angiography) = 534.15 USD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Direct medical monitoring costs in year 2 and thereafter (year ≥ 2) were equal to the adjusted number of injections (taking discontinuation and mortality into account) in year ≥ 2 multiplied by 184.58 USD (i.e., subsequent office visit + OCT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
OCT and fluorescein angiography use among Medicare retina specialists, 2012 to 2016
“National relative utilization of OCT increased from 61.5% in 2012 to 70.5% in 2016 (P < .001), while IVFA fell from 20.9% to 15.1% over the same interval (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fundus photography decreased from 14.6% in 2012 to 11.7% in 2016 (P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retinal imaging volume and anti-VEGF injection volume in Medicare, 2013 to 2021
“For anti-VEGF injections, a positive association in annual volume was observed with ocular coherence tomography ( P < 0.001, R 2 = 0.84), whereas negative associations were observed with FA ( P < 0.001, R 2 = 0.89) and FA + indocyanine-green angiography ( P < 0.001, R 2 = 0.90).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ocular coherence tomography continues to rise as a percentage of all retinal imaging ordered, whereas FA has declined.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Medicare and patient savings from OCT-guided anti-VEGF therapy, 2008 to 2015
“From 2008 – 2015, the United States government and nvAMD patients have accrued an estimated savings of $9.0 billion and $2.2 billion, respectively, from the use of OCT to guide personalized anti-VEGF treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Using the meta-analysis and survey data, we calculated the cost of using OCT imaging to guide anti-VEGF treatment decisions from 2008– 2015 was $0.8 billion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Anti-VEGF drugs, their injection and OCT imaging are covered under Medicare Part B, which requires beneficiaries to copay 20% of the Medicare-approved amount in the absence of supplementary Medigap insurance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imaging studies per beneficiary in Medicare, 1994 to 2006 cohorts
“There were significant increases in the mean yearly number of visits (2.1 vs. 3.5, p<0.0001), OCTs (0 vs. 2.1, <0.0001), and anti-VEGF injections (0 vs. 2.0, p<0.0001) between 1994 and 2006.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From 1994 to 2006, payments for fluorescein angiography remained essentially stable, while those for OCT increased significantly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
OCT-related visits by disease activity: U.S. commercial claims
| OCT test-related visits, prevalent cohort | All patients | Active CNV | Inactive CNV | Inactive scar |
|---|---|---|---|---|
| Patients with at least 1 visit, n (%) | “5,350 (88.1)”View highlighted excerpt for this quote | “3,384 (92.6)”View highlighted excerpt for this quote | “893 (85.4)”View highlighted excerpt for this quote | “253 (70.7)”View highlighted excerpt for this quote |
| Number of unique visits, mean (SD) | “4.5 (3.5)”View highlighted excerpt for this quote | “5.4 (3.6)”View highlighted excerpt for this quote | “2.9 (2.6)”View highlighted excerpt for this quote | “1.6 (1.9)”View highlighted excerpt for this quote |
Monitoring frequency in routine practice: U.S. claims, 2006 to 2011
“In the 2008-2010 cohorts (n = 10 259), mean annual number of injections remained low (bevacizumab: 4.6, 5.1, and 5.5; ranibizumab: 6.1, 6.6, and 6.9), as did mean numbers of ophthalmologist visits (bevacizumab only) and OCT examinations (both agents), but there was no such trend in FA examinations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the 2010 cohort, among bevacizumab- and ranibizumab-treated patients, respectively, less than 23% and less than 40% had at least 10 ophthalmologist visits, and less than 4% and less than 21% had at least 10 optical coherence tomography scans.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
OCT examinations per year and vision-related quality of life: Germany (ALBATROS)
“1478 patients (74.5 ± 10.9 years, 54.9% female) were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“8.8 ± 2.6 OCT examinations and 6.1 ± 3.2 intravitreal injections were performed within 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After twelve months, an increase in visual acuity and visual functional scale was observed for nAMD, DME, and BRVO, while in DME only, there was an association between number of OCT examinations and VRQoL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of OCT for diagnosis and monitoring: UK Health Technology Assessment
“For monitoring, the pooled sensitivity and specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The FFA for diagnosis and nurse-technician-led monitoring strategy had the lowest cost (£ 39,769; QALYs 10.473) and dominated all others except FFA for diagnosis and ophthalmologist-led monitoring (£ 44,649; QALYs 10.575; incremental cost-effectiveness ratio £ 47,768).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strategies involving OCT alone for diagnosis and/or monitoring were unlikely to be cost-effective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring tests for nAMD in the fellow eye: EDNA economic evaluation (UK)
“SD-OCT generated more QALYs (SD-OCT, 5.830; fundus assessment, 5.787; Amsler grid, 5.736, patient's subjective assessment, 5.630; and visual acuity, 5.600) and lower health and social care costs (SD-OCT, £19 406; fundus assessment, £19 649; Amsler grid, £19 751; patient's subjective assessment, £20 198 and visual acuity, £20 444) per patient compared with other individual monitoring tests.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilistic sensitivity analysis indicated a high probability (97%-99%) of SD-OCT being the preferred test across a range of cost-effectiveness thresholds (£13 000-£30 000) applied in the UK NHS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Community optometrist versus hospital monitoring of quiescent nAMD: cost per assessment (UK)
Approaches to treatment
Current treatment options and standard of care
Anti-VEGF monoclonal antibodies and antibody fragments
AAO Preferred Practice Pattern: anti-VEGF therapy as first-line treatment
AAO Preferred Practice Pattern: management options and agent selection
Cochrane systematic review of anti-VEGF agents versus control and bevacizumab versus ranibizumab
“We included 16 RCTs that had enrolled a total of 6347 participants with neovascular AMD (the number of participants per trial ranged from 23 to 1208) and identified one potentially relevant ongoing trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Visual acuity outcomes after bevacizumab and ranibizumab were similar when the same RCTs compared the same regimens with respect to gain of 15 or more letters of visual acuity (RR 0.95, 95% CI 0.81 to 1.12; high-certainty evidence) and loss of fewer than 15 letters of visual acuity (RR 1.00, 95% CI 0.98 to 1.02; high-certainty evidence)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Researchers reported endophthalmitis in less than 1% of anti-VEGF-treated participants and in no cases among control groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ranibizumab: FDA-approved dosing in neovascular AMD
Ranibizumab: label efficacy in the pivotal trials
Ranibizumab: warnings and precautions
Ranibizumab: MARINA sham-controlled trial
“We enrolled 716 patients in the study. At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“During 24 months, presumed endophthalmitis was identified in five patients (1.0%) and serious uveitis in six patients (1.3%) given ranibizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ranibizumab: ANCHOR trial versus verteporfin photodynamic therapy
“Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bevacizumab: off-label intravitreal use
Bevacizumab versus ranibizumab: CATT 1-year results
“In a multicenter, single-blind, noninferiority trial, we randomly assigned 1208 patients with neovascular AMD to receive intravitreal injections of ranibizumab or bevacizumab on either a monthly schedule or as needed with monthly evaluation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively. Bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients with serious systemic adverse events (primarily hospitalizations) was higher with bevacizumab than with ranibizumab (24.1% vs. 19.0%; risk ratio, 1.29; 95% confidence interval, 1.01 to 1.66)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bevacizumab versus ranibizumab: CATT 2-year results
“Among patients following the same regimen for two years, mean gain in visual acuity was similar for both drugs (bevacizumab-ranibizumab difference: −1.4 letters; 95% confidence interval (CI): [−3.7, 0.8]; p=0.21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The proportion of patients with ≥1 systemic serious adverse events was higher with bevacizumab than ranibizumab (39.9% vs. 31.7%; adjusted risk ratio 1.30; CI [1.07, 1.57]; p=0.009).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bevacizumab versus ranibizumab: IVAN 2-year results
“610 received study drugs (314 ranibizumab; 296 bevacizumab) and were included in analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For BCVA, bevacizumab was neither non-inferior nor inferior to ranibizumab (mean difference -1·37 letters, 95% CI -3·75 to 1·01; p=0·26).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ranibizumab and bevacizumab have similar efficacy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AAO Preferred Practice Pattern: comparative efficacy and safety of bevacizumab and ranibizumab
Bevacizumab, ranibizumab, and aflibercept: IRIS Registry real-world comparison
“Of 13 859 patients, 6723 received bevacizumab, 2749 received ranibizumab, and 4387 received aflibercept only for 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was no statistical difference in the age-adjusted or multivariate-adjusted mean logMAR VA change (standard deviation) at 1 year among treatment groups (-0.048 [0.44] bevacizumab, -0.053 [0.46] ranibizumab, -0.040 [0.39] aflibercept; P = 0.46).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bevacizumab: EURETINA guideline recommendation on regimen
“Bevacizumab, as needed, failed to meet NI equivalence to monthly ranibizumab, that is, bevacizumab used in a PRN regimen did not reach the superior visual outcome achievable with monthly ranibizumab. Therefore, choice of the proper (fixed monthly) regimen is relevant when off-label bevacizumab is used.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline NG82: anti-VEGF agents considered equivalent
AAO Preferred Practice Pattern: cost-effectiveness of bevacizumab and ranibizumab
Brolucizumab: description and approved dosing
Brolucizumab: HAWK and HARRIER 48-week results
“Patients (N = 1817) with untreated, active choroidal neovascularization due to age-related macular degeneration in the study eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At Week 48, each brolucizumab arm demonstrated noninferiority to aflibercept in BCVA change from baseline (least squares [LS] mean, +6.6 [6 mg] and +6.1 [3 mg] letters with brolucizumab vs. +6.8 letters with aflibercept [HAWK]; +6.9 [brolucizumab 6 mg] vs. +7.6 [aflibercept] letters [HARRIER]; P < 0.001 for each comparison).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Greater than 50% of brolucizumab 6 mg-treated eyes were maintained on q12w dosing through Week 48 (56% [HAWK] and 51% [HARRIER]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Brolucizumab: HAWK and HARRIER 96-week results
Brolucizumab: retinal vasculitis and retinal vascular occlusion warning
Brolucizumab: Safety Review Committee analysis of intraocular inflammation in HAWK and HARRIER
“On the basis of these cases, incidence of definite/probable IOI was 4.6% (IOI + vasculitis, 3.3%; IOI + vasculitis + occlusion, 2.1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence of IOI in aflibercept-treated eyes was 1.1%, with at least moderate visual acuity loss in 0.14%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Brolucizumab: MERLIN every-4-week dosing terminated for intraocular inflammation
“Incidence of intraocular inflammation (IOI), including retinal vasculitis and retinal vascular occlusion, were 9.3% (0.8% and 2.0%) for brolucizumab versus 4.5% (0% and 0%) for aflibercept, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, incidences of IOI, including retinal vasculitis and retinal vascular occlusion, also were higher, leading to study termination.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Incidence of intraocular inflammation (IOI), including retinal vasculitis and retinal vascular occlusion, was 11.5% (0.8% and 2.2%) for brolucizumab versus 6.1% (0% and 0.6%) for aflibercept.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“therefore, brolucizumab should not be used more frequently than every 8 weeks after the loading regimen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AAO Preferred Practice Pattern: brolucizumab safety
Medicare Advantage step therapy for Part B drugs: CMS policy
Medicare Advantage step therapy: bevacizumab-first payer policy example
Step therapy: bevacizumab-first policies and supply disruption
ASRS Preferences and Trends survey: agent switching after suboptimal bevacizumab response
VEGF trap fusion proteins
AAO Preferred Practice Pattern: aflibercept 2 mg
Aflibercept 2 mg: FDA-approved dosing
Aflibercept 2 mg: VIEW 1 and VIEW 2 trials
“Patients (n = 2419) with active, subfoveal, choroidal neovascularization (CNV) lesions (or juxtafoveal lesions with leakage affecting the fovea) secondary to AMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All aflibercept groups were noninferior and clinically equivalent to monthly ranibizumab for the primary end point (the 2q4, 0.5q4, and 2q8 regimens were 95.1%, 95.9%, and 95.1%, respectively, for VIEW 1, and 95.6%, 96.3%, and 95.6%, respectively, for VIEW 2, whereas monthly ranibizumab was 94.4% in both studies).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aflibercept 2 mg: label efficacy and warnings
Aflibercept 8 mg: FDA-approved dosing
Aflibercept 8 mg: PULSAR 48-week results
“Of 1011 patients randomised to aflibercept 8q12 (n=336), 8q16 (n=338), or 2q8 (n=337) between Aug 11, 2020, and July 30, 2021, 1009 patients received study treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Aflibercept 8q12 and 8q16 showed non-inferior BCVA gains versus aflibercept 2q8 (mean BCVA change from baseline +6·7 [SD 12·6] and +6·2 [11·7] vs +7·6 [12·2] letters).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of ocular adverse events in the study eye was similar across groups (aflibercept 8q12 n=129 [39%]; aflibercept 8q16 n=127 [38%]; and aflibercept 2q8 n=130 [39%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aflibercept 8 mg: PULSAR interval maintenance at week 48
Aflibercept 8 mg: label injection counts and intervals through week 96
Aflibercept 8 mg: PULSAR 96-week outcomes by baseline disease severity
“Overall, 869 patients completed treatment through week 96.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients in the aflibercept 8q12 and 8q16 arms achieved visual and anatomic outcomes at week 96 comparable to those in the aflibercept 2q8 arm within subgroups defined by baseline disease severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline NG82: aflibercept recommendation
Injections received in VIEW 1 and VIEW 2 through weeks 52 and 96
“The mean number of active injections received by patients in all monthly treatment arms, which were scheduled to receive 13 monthly injections, was 12.1 to 12.5 in VIEW 1 and 12.2 to 12.4 in VIEW 2.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The total number of active injections (baseline to week 96) was 16.0 to 16.2 in the monthly intravitreal aflibercept groups, 16.5 in the monthly ranibizumab group, and 11.2 in the original 2q8 group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring schedule in year 1 and the modified quarterly protocol in year 2 of VIEW 1 and VIEW 2
“Patients were examined on the day of treatment initiation and every 4 weeks thereafter through 52 weeks, as well as 1 week after first treatment for safety assessment (subsequent safety assessments occurred by telephone).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After the 1-year primary end point of VIEW 1/VIEW 2 presented in this article, all treatment groups’ dosing intervals were changed to a common protocol of modified quarterly dosing with their originally randomized dose and drug (all patients were monitored monthly and received a minimum of dosing every 12 weeks with interim as-needed monthly intravitreal injections).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Injection-related serious ocular adverse events per 1000 injections in VIEW 1 and VIEW 2
“The combined data for both studies showed a rate of events/1000 injections of 1.1, 0.8, 0.1, and 0.2 for the ranibizumab 0.5q4 and intravitreal aflibercept 2q4, 0.5q4, and 2q8 groups, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These events included eye disorders, endophthalmitis, procedural complications, and increased intraocular pressure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
PULSAR criteria for shortening the aflibercept 8 mg dosing interval
“Beginning at week 16, patients receiving aflibercept 8 mg were assessed and the dosing interval was shortened if the following DRM criteria were met: BCVA loss of more than 5 letters from week 12 and either a more than 25 μm increase in central retinal thickness (CRT) from week 12 or new foveal haemorrhage or neovascularisation” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients in the aflibercept 8q12 and 8q16 groups who met the DRM criteria at week 16 or week 20 had their interval shortened and subsequently received aflibercept 8 mg every 8 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ocular and systemic safety in PULSAR through week 48
“Serious ocular TEAEs in the study eye occurred in 13 (1·3%) of 1009 patients” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In PULSAR, rates of intraocular inflammation with aflibercept were low, and there were no cases of endophthalmitis or retinal vasculitis up to week 48.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All cases of intraocular inflammation were mild or moderate in severity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eight cases of arteriothrombotic events, assessed and categorised by an Anti-Platelet Trialists’ Collaboration adjudication committee, were reported, with no clinically relevant differences observed across groups” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Bispecific Anti-VEGF/Angiopoietin-2 antibodies
AAO Preferred Practice Pattern: faricimab
Faricimab: TENAYA and LUCERNE primary results
“Across the two trials, 1329 patients were randomly assigned between Feb 19 and Nov 19, 2019 (TENAYA n=334 faricimab and n=337 aflibercept), and between March 11 and Nov 1, 2019 (LUCERNE n=331 faricimab and n=327 aflibercept).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“BCVA change from baseline with faricimab was non-inferior to aflibercept in both TENAYA (adjusted mean change 5·8 letters [95% CI 4·6 to 7·1] and 5·1 letters [3·9 to 6·4]; treatment difference 0·7 letters [-1·1 to 2·5]) and LUCERNE (6·6 letters [5·3 to 7·8] and 6·6 letters [5·3 to 7·8]; treatment difference 0·0 letters [-1·7 to 1·8]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Faricimab: TENAYA and LUCERNE 2-year results with treat-and-extend dosing
“At week 112 in TENAYA and LUCERNE, 59.0% and 66.9%, respectively, achieved Q16W faricimab dosing, increasing from year 1, and 74.1% and 81.2%, achieved Q12W or longer dosing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ocular AEs in the study eye were comparable between faricimab and aflibercept groups in TENAYA (55.0% and 56.5% of patients, respectively) and LUCERNE (52.9% and 47.5% of patients, respectively) through week 112.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Faricimab: label dosing-interval distribution and FDA caveats
Faricimab: safety
Faricimab: real-world use in previously treated eyes (TRUCKEE)
NICE technology appraisal TA800: faricimab
Network meta-analysis of anti-VEGF agents and regimens
“Forty‐nine RCTs including 23 257 eyes of 23 257 patients were included. No anti‐VEGF drug or treatment regimen provided a better BCVA response compared to the reference.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“When results are considered simultaneously, faricimab 6.0 mg or aflibercept 8.0 mg in a treatment regimen with an LD followed by either a treat‐and‐extend regimen or a fixed 12‐ or 16‐week regimen appears to provide the optimal balance between visual outcomes, anatomical outcomes and the lowest treatment burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fixed dosing without rescue treatment in TENAYA and LUCERNE
“From day 1, patients randomly assigned to the faricimab group initially received intravitreal faricimab 6·0 mg every 4 weeks up to week 12 (four injections) and patients in the aflibercept group received intravitreal aflibercept 2·0 mg, per its international label guidance, every 4 weeks up to week 8 (three injections), followed by fixed 8-week dosing to study end, without allowing rescue or additional treatments during the study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients in the faricimab group who did not have active disease at weeks 20 and 24 received faricimab at week 28 and continued a 16-week regimen up to week 60.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Intraocular inflammation and endophthalmitis in TENAYA and LUCERNE at week 48
“Rates of intraocular inflammation were low across both trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In TENAYA and LUCERNE, at week 48, rates of intraocular inflammation were low and on average reported in 2·0% of patients receiving faricimab and 1·2% of patients receiving aflibercept” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was one report of endophthalmitis in the aflibercept group of LUCERNE, which was culture negative.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treat-and-extend interval rules and maintenance of extended intervals in year 2
“In brief, dosing intervals could be extended by 4 weeks (up to Q16W) if the patient achieved stable anatomic features, vision, and no new macular hemorrhage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The interval was reduced by 4- or 8-week increments (as low as Q8W) if worsening vision or anatomic features were found, or new macular hemorrhage occurred” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On average, 71% of patients who achieved the extended dosing interval of Q12W or longer during the fixed-dosing phase in year 1 maintained Q12W or longer dosing without a reduction to Q8W dosing during the T&E PTI dosing phase through year 2” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, 69% of patients receiving Q16W dosing during the fixed-dosing phase in year 1 continued to receive that treatment interval without deviation during the T&E PTI dosing phase” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Serious ocular adverse events and intraocular inflammation through week 112
“The proportion of patients with serious ocular AEs in the study eye through week 112 was low and comparable across study arms in TENAYA (faricimab up to Q16W, 14 patients [4.2%]; aflibercept Q8W, 13 patients [3.9%]) and LUCERNE (faricimab up to Q16W, 15 patients [4.5%]; aflibercept Q8W, 16 patients [4.9%]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of intraocular inflammation (IOI) events through week 112 was low and comparable between patients receiving faricimab up to Q16W (TENAYA, 11 events [3.3%]; LUCERNE, 9 events [2.7%]) and aflibercept Q8W (TENAYA, 5 events [1.5%]; LUCERNE, 10 events [3.1%]; Table 5)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“All IOI events except 1 were nonserious.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Also, no new retinal vasculitis or noninflammatory occlusive events were reported, in line with their absence at the primary analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Anti-VEGF biosimilars
FDA-approved ranibizumab and aflibercept biosimilars
| Nonproprietary name | Biosimilar product | Approval date | Reference product |
|---|---|---|---|
| Ranibizumab-nuna | “Byooviz (ranibizumab-nuna)” | “September 2021” | “Lucentis (ranibizumab)” |
| Ranibizumab-eqrn | “Cimerli (ranibizumab-eqrn)” | “August 2022” | “Lucentis (ranibizumab)” |
| Ranibizumab-leyk | “Nufymco (ranibizumab-leyk)” | “December 2025” | “Lucentis (ranibizumab)” |
| Ranibizumab-hkdz | “Ranluspec (ranibizumab-hkdz)” | “June 2026” | “Lucentis (ranibizumab)” |
| Aflibercept-yszy | “Opuviz (aflibercept-yszy)” | “May 2024” | “Eylea (aflibercept)” |
| Aflibercept-jbvf | “Yesafili (aflibercept-jbvf)” | “May 2024” | “Eylea (aflibercept)” |
| Aflibercept-mrbb | “Ahzantive (aflibercept-mrbb)” | “June 2024” | “Eylea (aflibercept)” |
| Aflibercept-abzv | “Enzeevu (aflibercept-abzv)” | “August 2024” | “Eylea (aflibercept)” |
| Aflibercept-ayyh | “Pavblu (aflibercept-ayyh)” | “August 2024” | “Eylea (aflibercept)” |
| Aflibercept-boav | “Eydenzelt (aflibercept-boav)” | “October 2025” | “Eylea (aflibercept)” |
AAO Preferred Practice Pattern: biosimilar approval standard and product choice
AAO Preferred Practice Pattern: aflibercept biosimilar dosing
Ranibizumab-nuna: biosimilar labeling and dosing
Ranibizumab biosimilar SB11: phase 3 equivalence trial
“This randomized, double-masked, parallel-group phase 3 equivalence study was conducted in 75 centers in 9 countries from March 14, 2018, to December 9, 2019, among 705 participants 50 years or older with neovascular age-related macular degeneration with active subfoveal choroidal neovascularization lesions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Least-squares mean (SE) changes in BCVA from baseline at week 8 were 6.2 (0.5) letters in the SB11 group vs 7.0 (0.5) letters in the ranibizumab group, with an adjusted treatment difference of −0.8 letter (90% CI, −1.8 to 0.2 letters).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Immunogenicity was low, with a cumulative incidence of antidrug antibodies up to week 24 of 3.0% (10 of 330) in the SB11 group and 3.1% (10 of 327) in the ranibizumab group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ranibizumab biosimilar FYB201: COLUMBUS-AMD equivalence trial
“A total of 477 patients were randomly assigned to receive FYB201 (n = 238) or reference ranibizumab (n = 239).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The analysis of covariance (ANCOVA) least squares mean difference for the change from baseline between FYB201 and reference ranibizumab was -0.4 ETDRS letters with a 90% confidence interval (CI) of -1.6 to 0.9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AAO Preferred Practice Pattern: Medicare prices and modeled savings from biosimilars
Refillable port delivery system
Ranibizumab port delivery system: boxed warning for endophthalmitis
Ranibizumab port delivery system: indication and dosing
Ranibizumab port delivery system: Archway phase 3 trial
“Archway enrolled 418 patients; 251 were randomized to and 248 received treatment with the PDS Q24W, and 167 were randomized to and received treatment with monthly ranibizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted mean change in BCVA score from baseline averaged over weeks 36 and 40 was +0.2 letters (standard error [SE], 0.5 letters) in the PDS Q24W arm and +0.5 letters (SE, 0.6 letters) in the monthly ranibizumab arm (difference, -0.3 letters; 95% confidence interval, -1.7 to 1.1 letters).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Prespecified ocular adverse events of special interest were reported in 47 patients (19.0%) in the PDS Q24W arm and 10 patients (6.0%) in the monthly ranibizumab arm, which included, in the former arm, 4 (1.6%) endophthalmitis cases, 2 (0.8%) retinal detachments, 13 (5.2%) vitreous hemorrhages, 6 (2.4%) conjunctival erosions, and 5 (2.0%) conjunctival retractions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ranibizumab port delivery system: label supplemental treatment and endophthalmitis rates
Ranibizumab port delivery system: septum dislodgement
Ranibizumab port delivery system: endophthalmitis case series across clinical trials
“Twelve endophthalmitis events were reported in 11 patients (11/555 [2.0%]) through March 12, 2021.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Seven cases (7/11 [63.6%]) had preceding/concurrent conjunctival complications. At last follow-up, 7 patients recovered vision to study baseline levels or ≥20/40; 4 patients experienced vision loss of ≥15 ETDRS letters.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ranibizumab port delivery system: Portal extension trial
“In the All-PDS safety population (mean follow-up, 111 weeks), 137 (24.7%) patients had ≥1 ocular AESI; most common were cataract (11.4%), vitreous hemorrhage (6.1%), and conjunctival thickening (bleb)/filtering bleb leak (6.3%). Endophthalmitis occurred in 11 of 555 (2.0%) patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Approximately 95% of patients did not need supplemental treatment before each refill-exchange for >2 years since Portal enrollment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ranibizumab port delivery system: 5-year Portal results
Ranibizumab port delivery system: voluntary recall and reintroduction
AAO Preferred Practice Pattern: port delivery system risks and cost-effectiveness
Timing of endophthalmitis after port delivery system implantation
“There were 2 cases (2/555 [0.4%]) of postoperative endophthalmitis consistent with acute postoperative endophthalmitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The range of onset for all other cases was 57 to 853 days after the PDS implant insertion procedure (Table 3), including 6 cases occurring in the first year after the PDS implant insertion procedure and 1 case occurring >2 years after the PDS implant insertion procedure (Fig 2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The retraction cases presented relatively earlier in the first year after surgery, with onset ranging between 2 to 6 months after implantation surgery, whereas the erosion cases presented later, with onset ranging from 20 to 28 months after implantation surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Severity, organisms, and management of port delivery system endophthalmitis cases
“all patients experienced moderate (4/11 [36.4%]) or severe (7/11 [63.6%]) endophthalmitis when events were analyzed by greatest intensity.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Three cases of endophthalmitis were culture positive (1 case each of Streptococcus pneumoniae, Enterococcus faecalis, Staphylococcus aureus; the case positive for E. faecalis reported history of exposure to a septic tank 1 week prior).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Vitrectomy was performed for endophthalmitis in 5 cases; vitrectomy and a scleral wound revision was performed after endophthalmitis had resolved for 1 additional case to treat a subsequent event of wound leak/hypotony.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Six patients had the PDS implant removed after their endophthalmitis episode per surgeon's preference, and 1 patient with endophthalmitis associated with E. faecalis discontinued refills but retained the implant at the surgeon's discretion.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Serious ocular adverse events of special interest in the pooled port delivery system population
“Other important ocular AESIs included conjunctival erosion (reported in 4.0% [22/555] of patients), conjunctival retraction (1.8% [10/555]), endophthalmitis (2.0% [11/555]), hyphema (1.6% [9/555]), implant dislocation (1.1% [6/555]), rhegmatogenous retinal detachment (0.7% [4/555]), and septum dislodgement (0.5% [3/555]) (Table 6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among ocular AESIs reported as serious, the most common were endophthalmitis (1.8% [10/555]), conjunctival erosion (1.3% [7/555]), and conjunctival retraction (0.9% [5/555]; Table 6).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 73.0% (27/37) of vitreous hemorrhage events were mild; most (91.9% [34/37]) resolved with observation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of conjunctival bleb events involved fluid and most resolved after approximately 11 (mean, 11.21) weeks, without the need for additional procedures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Septum dislodgement and the 2022 voluntary recall
“Since the March 2021 data cut used for the current analysis, there were an additional 30 septum dislodgements to August 2022 across the PDS clinical trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Due to additional testing conducted during an investigation into septum dislodgement cases in phase III clinical trials, Roche/Genentech initiated a voluntary recall of the PDS Ocular Implant and Insertion Tool Assembly in October 2022 and paused all new implantations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Number and timing of supplemental injections between refill-exchanges in Portal
“Across all treatment arms, 39 supplemental treatments were administered in 21 patients (data not shown).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 32 supplemental treatments occurred 8 weeks before a refill-exchange, and 7 occurred 4 weeks before a refill-exchange.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 21 patients, 9 received 1 treatment, 9 received 2 treatments, 2 received 3 treatments, and 1 received 5 treatments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ocular adverse events associated with persistent vision loss and their timing
“Six of 7 episodes of conjunctival erosion that occurred across the analysis period were associated with significant persistent vision loss, of which 2 were repeat events.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One episode of endophthalmitis occurred 2.3 years after implantation in Ladder and was attributed to the refill-exchange procedure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As shown by the distribution of ocular AESIs over time, all events that occurred >2 years after PDS implantation were in patients who received the PDS implant earlier in the PDS clinical trial program, and surgical procedures have since been further optimized.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Supplemental treatment before the first refill-exchange in Archway
“Of 246 PDS-treated patients assessed for supplemental ranibizumab treatment, 242 (98.4%) did not receive supplemental ranibizumab treatment before the first refill-exchange procedure, including 4 patients who discontinued treatment before the first refill-exchange procedure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 4 PDS-treated patients (1.6%) who were assessed for supplemental treatment received supplemental treatment before the first refill-exchange procedure.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Timing and surgical management of ocular adverse events in Archway
“Most ocular adverse events in the PDS Q24W arm occurred within 1 month of implantation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“endophthalmitis occurred in 4 patients (1.6%) in the PDS Q24W arm; all events were serious and occurred outside of the postoperative period at days 57, 59, 161, and 282. Three of the 4 events were associated with conjunctival retraction.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Conjunctival erosion and conjunctival retraction events occurred in 6 patients (2.4%) and 5 patients (2.0%) in the PDS Q24W arm, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 9 of 11 patients required additional surgery, and events were addressed with conjunctival flap revisions; 3 repairs were performed using split-thickness corneal graft.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Vitreous hemorrhage, conjunctival bleb, and unscheduled visits in Archway
“Vitreous hemorrhage occurred in 13 patients (5.2%) in the PDS Q24W arm; 1 event was serious and 12 of 13 events occurred in the postoperative period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eleven of 13 hemorrhages (84.6%) were grade 1 or 2 based on functional impact (Table S2, available at www.aaojournal.org), and all events resolved spontaneously without vitrectomy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Conjunctival bleb or conjunctival filtering bleb leak events were reported in 16 patients (6.5%) in the PDS Q24W arm. All events were nonserious.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of these 47 PDS patients, 16 underwent at least 1 unscheduled visit within 7 days of occurrence of an ocular adverse event of special interest, and 18 underwent at least 1 unscheduled visit within 14 days of occurrence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Photodynamic therapy and thermal laser photocoagulation
AAO Preferred Practice Pattern: role of verteporfin photodynamic therapy
Verteporfin: FDA-approved indication
Verteporfin photodynamic therapy: TAP trials
“Six hundred nine patients were randomly assigned (2: 1) to verteporfin (6 mg per square meter of body surface area) or placebo (5% dextrose in water) administered via intravenous infusion of 30 mL over 10 minutes.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the month-12 examination, 246 (61%) of 402 eyes assigned to verteporfin compared with 96 (46%) of 207 eyes assigned to placebo had lost fewer than 15 letters of visual acuity from baseline (P<.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Verteporfin photodynamic therapy: complications
NICE guideline NG82: photodynamic therapy
AAO Preferred Practice Pattern: thermal laser photocoagulation
Macular Photocoagulation Study: 5-year results for extrafoveal lesions
“In eyes with senile (age-related) macular degeneration as the underlying cause, the relative risk of losing six or more lines of visual acuity from the baseline level among untreated eyes (n = 117) compared with laser-treated eyes (n = 119) was 1.5 from 6 months through 5 years after entry (P = .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Recurrent neovascularization had been observed in 54% of laser-treated eyes by the end of the 5-year follow-up period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary
Current therapies control exudation but do not cure neovascular AMD, and all FDA-approved options require ongoing intravitreal injections or, for the port delivery system, surgery and refills every 24 weeks. Efficacy observed in registration trials is not reproduced in routine practice. In a US database of 49,485 treatment-naive eyes, participants received a mean of 7.3 injections in year 1 and gained a mean of 0.95 letters, and in SIERRA-AMD (98,821 eyes) mean visual acuity change was -5.2 letters by year 4. In the 1,208-participant CATT trial, 5-year mean change was -3 letters from baseline and -11 letters from year 2, and in SEVEN-UP 34% of study eyes had declined by 15 letters or more at a mean of 7.3 years. Treatment burden contributes to undertreatment: a systematic review of 37 studies reported nonpersistence in up to 50% of patients by 24 months and nonadherence in 32% to 95%; loss to follow-up was 22.2% among 9,007 participants in one US practice cohort; and 48.8% of 130 Norwegian survey respondents received 9 or more injections per year, with 37.7% requiring caregiver support at every appointment. Response is heterogeneous, and there is no consensus definition of non-response. Safety constraints limit some options: brolucizumab carries warnings for retinal vasculitis and retinal vascular occlusion, and the port delivery system carries a boxed warning for an up to 3-fold higher rate of endophthalmitis. Payer step therapy requiring bevacizumab first can delay access to FDA-approved agents.
Real-world visual outcomes and injection frequency: US database of 49,485 eyes
“At 1 year, after a mean of 7.3 anti-VEGF injections, there was a mean gain of 1 letter (0.95 letter; 95% confidence interval [CI] for change in VA, +0.77 to +1.13 letter; P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Real-world nAMD patients receive fewer anti-VEGF injections and experience worse visual outcomes compared with patients receiving fixed, frequent therapy in randomized controlled trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world visual outcomes over 4 years: SIERRA-AMD
“A total of 98 821 eyes from 79 885 patients receiving intravitreal anti-VEGF therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In eyes with 4-year follow-up, VA changes from baseline (ETDRS letters) were least squares means of +1.1 (95% confidence interval [CI], 1.0;1.3), -1.3 (95%CI, -1.5;-1.0), and -3.1 (95%CI, -3.5;-2.7), and -5.2 (95%CI, -6.0;-4.3) for years 1-4. Mean±SD number of injections was 7.5±1.9, 6.7±2.1, 6.6±2.3, and 6.4±2.3 for years 1-4.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Undertreatment in real-world practice: literature review
“In real-world practice, patients are usually undertreated, accounting for the VA decline over time. Reasons for undertreatment include the burden of injections and monitoring visits imposed on patients/caregivers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world injection number and outcomes: AURA and LUMINOUS
“Patients who received >7 injections (in 1 year) or >14 injections (over 2 years) gained more letters and demonstrated greater vision maintenance (loss of <15 letters) than patients who received fewer injections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world outcomes in the United Kingdom: systematic review
“Twenty-six studies (n=25,761 eyes) were included” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Longer-term studies reported that the visual gains achieved in the first year of treatment were rarely maintained, with under-treatment a likely contributing factor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term visual decline: CATT 5-year follow-up
“VA was obtained for 647 (71%) of 914 living patients with average follow-up time 5.5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean change in VA was -3 letters from baseline and -11 letters from 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vision gains during the first 2 years of the trial were not maintained at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term visual decline: SEVEN-UP 7-year follow-up
“Forty-three percent of study eyes had a stable or improved letter score (≥0-letter gain) compared with ANCHOR or MARINA baseline measurements, whereas 34% declined by 15 letters or more, with overall a mean decline of 8.6 letters (P<0.005).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Macular atrophy was detected by FAF in 98% of eyes, with a mean area of 9.4 mm(2); the area of atrophy correlated significantly with poor visual outcome (P<0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AAO Preferred Practice Pattern: real-world treatment and loss to follow-up
Loss to follow-up: systematic review and meta-analysis
“We included 52 studies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“LTFU rates ranged from <5% to >75% over up to 10 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who were LTFU had worse visual outcomes even after resuming care.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Nonadherence and nonpersistence: systematic review
Nonadherence increases with treatment duration
Treatment burden: patient-reported survey
“In total, 130 patients responded to the survey. The majority of patients reported to receive nine or more injections per year (48.8%), and many patients needed caregiver support for every treatment appointment (37.7%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Responders included 910 patients and 890 caregivers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most patients and caregivers reported a number of obstacles in managing wAMD, including the treatment itself (35% and 39%, respectively). Sixteen percent of patients also missed a clinic visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ASRS Preferences and Trends survey: reasons for real-world undertreatment
Heterogeneous response and lack of a consensus definition of non-response
“Furthermore, a proportion of eyes with n-AMD show a decline in acuity or morphology, despite therapy or require very frequent re-treatment. There is currently no consensus as to how to classify optimal response, or lack of it, with these therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline NG82: limited benefit of switching agents
Injection counts associated with vision loss, linear gain, and plateau in United States practice
“At the lower range, those patient eyes that received 4 anti-VEGF injections or fewer in the first year of treatment generally lost vision, approximately 2 to 3 letters at 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the mid range, a linear relationship was found between mean letters gained and mean number of anti-VEGF injections, up to 10 injections over 1 year, after which the relationship plateaued at approximately 3 to 4 letters gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Older age and worse baseline visual acuity among eyes receiving the fewest injections
“Patient eyes that received 4 anti-VEGF injections or fewer over 1 year generally showed worse mean baseline VA than those patient eyes that received a greater number of injections over 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Those who received 1 anti-VEGF injection had a mean baseline age of 81.1 years, whereas those who received 13 injections over 1 year had a mean baseline age of 78.4 years (Fig 3; Table 3).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
One-year visual acuity change by baseline visual acuity at similar injection frequency
“Specifically, patients with baseline VA of 20/200 or worse, 20/70 to 20/200, 20/40 to 20/70, and 20/40 or better received 6.5, 7.4, 7.5, and 7.3 anti-VEGF injections, respectively, over 1 year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with baseline VA of 20/40 or better tended to lose VA at 1 year, regardless of anti-VEGF injection frequency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Adherence, missed visits, and visual acuity in routine anti-VEGF care
“In unadjusted univariable analyses, treatment adherence was related to a higher most recent VA (β = 8.98 letters; CI, 1.34–16.62) and lower odds of VA below driving vision (≤69 letters vs. ≥ 70 letters) (OR = 0.50; CI, 0.25–1.00) among nAMD patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Number of missed visits was associated with lower most recent VA and lower odds of VA below driving vision in nAMD patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“nAMD patients who received more injections had better self-reported NEIVFQ-25 composite scores in unadjusted analyses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Retina specialist views on monitoring and injection frequency as a resource burden
“When asked about the impact of activities for monitoring and injection administration on staff time, the majority of the surveyed retina specialists (62%, 35 of 57) felt that frequency of patient monitoring placed a significant burden on staff time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Forty-nine percent (28 of 57) of retina specialists reported that the frequency of injections was an impactful burden on office space, including waiting rooms and examination rooms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Over one-third of physicians (35%, 20 of 57) considered frequency of patient monitoring to be an important motivator in choosing a treatment to prescribe. Two-thirds of physicians (38 of 57) stated they would find it very desirable to reduce office visits.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary
The axitinib intravitreal implant is investigational and has no established place in therapy. If approved, it would be the first tyrosine kinase inhibitor marketed for nAMD. Its pivotal evidence comes from adults aged 50 years or older with newly diagnosed nAMD: SOL-1 randomized 344 treatment-naive participants who, after two aflibercept 2 mg loading doses, reached a BCVA of about 20/20 or gained at least 10 letters with CSFT of 350 µm or less; SOL-R randomized 640 treatment-naive or recently diagnosed participants after a 6-month lead-in that excluded eyes with early persistent fluid or significant fluid fluctuation. No pivotal trial has enrolled previously treated participants with established disease; only the 21-participant U.S. phase 1 trial enrolled previously treated, anti-VEGF-responsive participants, using a different formulation. The sponsor anticipates a label allowing redosing every 6 to 12 months and positions the product as a maintenance treatment after anti-VEGF loading. Anticipated administration is an intravitreal injection with a 25-gauge needle by retina specialists in the office setting, the same care setting as current anti-VEGF injections, without concomitant corticosteroids. Sponsor-funded market research reports that about 80% of surveyed retina specialists would be likely to use a product with this profile; these data have not been independently published. Independent reviewers state that larger controlled trials are needed to define the role of sustained-release tyrosine kinase inhibitors in clinical practice.
Anticipated position as the first tyrosine kinase inhibitor for nAMD
Studied population: SOL-1 treatment-naive participants responding to aflibercept loading
Studied population: sponsor description of SOL-1 enrollment
Studied population: SOL-R treatment-naive or recently diagnosed participants
Previously treated population: U.S. phase 1 trial only
Anticipated dosing interval: sponsor projection
Sponsor rationale for early initiation
Care setting: office-based intravitreal injection by retina specialists
Anticipated uptake: sponsor-funded market research
Role of sustained-release tyrosine kinase inhibitors: independent review
Use in previously treated or anti-VEGF-refractory nAMD, fellow eyes, and switching from other agents
No evidence found.
Uptake of longer-interval agents in Medicare as an indicator of clinician preference for durability
“The increasing preference for aflibercept and faricimab suggests that clinicians are gravitating toward agents that balance efficacy with reduced injection frequency.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The significant growth in faricimab use, despite its relatively high cost, suggests clinicians value extended treatment durability and reduced patient burden.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The consistent escalation in total Medicare spending underscores the financial impact of intravitreal therapy on the US health care system, a trend that may be tempered by the introduction of biosimilars and alternative delivery systems.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Independent assessment of the evidence still needed for sustained-release tyrosine kinase inhibitors
“Intravitreal agents such as OTX-TKI and EYP-1901 have demonstrated encouraging durability and safety profiles in early-phase trials.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sustained delivery of VEGF receptor TKIs represents a promising frontier in the management of retinal and choroidal vascular diseases. The ability to reduce treatment burden while maintaining safety and efficacy addresses a significant unmet need in this space.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ongoing phase 2 and 3 trials will be critical in determining which of these novel delivery systems can meaningfully reduce treatment burden while preserving vision outcomes” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Heterogeneity of treatment effect
Distribution of the SOL-1 population across the stratification category
Visual acuity outcomes by screening BCVA quartile: post hoc analysis
Outcomes restricted to rescue-free participants: post hoc analysis
Rescue criteria as a source of variation in estimated durability
Enriched SOL-R population and expected differences in response
Differences between phase 1 populations
Baseline vision of SOL-1 compared with other nAMD trial populations
Subgroup efficacy results by age, sex, race or ethnicity, lesion type, or baseline fluid
No evidence found.
Care management intervention strategies
AAO Preferred Practice Pattern: dosing regimens and follow-up
AAO Preferred Practice Pattern: treat-and-extend and as-needed (PRN) regimens
As-needed dosing: CATT and IVAN regimen comparisons
“Mean gain was greater for monthly than for as-needed treatment (difference: −2.4 letters; CI: [−4.8, −0.1]; p=0.046).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Switching from monthly to as-needed treatment resulted in greater mean decrease in vision during year 2 (−2.2 letters, p=0.03) and a lower proportion without fluid (−19%, p<0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1·63 letters, -4·01 to 0·75; p=0·18).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Reduction in the frequency of retreatment resulted in a small loss of efficacy irrespective of drug.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treat-and-extend: TREX-AMD 2-year results
“Sixty patients were enrolled and 50 completed month 24, at which point mean ETDRS BCVA letter gains were similar: 10.5 and 8.7 for the monthly and TREX cohorts, respectively (P = 0.64).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Through month 24, the mean number of injections administered was 25.5 (range, 22-27) and 18.6 (range, 10-25) for the monthly and TREX cohorts, respectively (P < 0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treat-and-extend: TREX-AMD third-year results
“Transition from Monthly to PRN was associated with a decline in best corrected visual acuity (BCVA) (+10.5 letters (month 24) to +5.4 (M36, p=0.09))” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Outcomes among subjects continued on TREX were more favourable, with a mean gain of +5.0 letters at M36.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treat-and-extend: CANTREAT 24-month results
“Participants included 580 patients with treatment-naive choroidal neovascularization secondary to AMD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“By the end of month 24, 466 of the 580 randomized patients (80.3%) had completed the study and participants in the T&E arm received a mean of 17.6 injections compared with 23.5 injections for the monthly arm, for a difference of 5.9 injections and visits over 2 years (95% CI, 5.4-6.5; P < .001). The mean (SD) BCVA improvement was not worse with the T&E arm, 6.8 (14.1) letters vs 6.0 (12.6) letters, compared with the monthly arm (difference, 0.9; 95% CI, −1.6 to 3.3; P = .21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treat-and-extend with aflibercept: ALTAIR and ARIES
“Over 52 weeks, mean number of injections was 7.2 and 6.9 and mean last injection interval was 10.7 and 11.8 weeks, for the 2- and 4-week groups, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Last injection interval before week 52 was at least 12 weeks in 42.3% and 49.6% of patients and 56.9% and 60.2% before week 96.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two-hundred seventy-one patients were randomized.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The last injection interval (W104) was ≥12W for 47.2% and 51.9% of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EURETINA guideline: monitoring schedules after treatment
“Patients who have received treatment should be monitored at regular intervals, according to a standardised strategy, either monthly or following an individualised pro-re-nata (PRN) or treat-and-extend regimen.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline NG82: timely treatment and OCT monitoring
Home monitoring for fellow-eye conversion: HOME study of the ForeseeHome device
“Seven hundred sixty-three participants were randomized to device monitoring and 757 participants were randomized to standard care and were followed up for a mean of 1.4 years between July 2010 and April 2013.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis achieved statistical significance, with the participants in the device arm demonstrating a smaller decline in visual acuity with fewer letters lost from baseline to CNV detection (median, -4 letters; interquartile range [IQR], -11.0 to -1.0 letters) compared with standard care (median, -9 letters; IQR, -14.0 to -4.0 letters; P = 0.021), resulting in better visual acuity at CNV detection in the device arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AAO Preferred Practice Pattern: self-monitoring and electronic monitoring devices
Home OCT self-imaging: prospective study
“The mean weekly scan frequency was 5.7 ± 0.9 scans per week, and 93% of the scans were eligible for NOA analyses. The median scan time was 42 seconds.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The NVHO scans analyzed using NOA and the in-office OCT scans graded by human experts agreed on the fluid status in 96% of the cases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Home OCT: FDA De Novo authorization
AREDS2 supplements for the fellow eye
AREDS2 randomized trial
“The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, randomized, double-masked, placebo-controlled phase 3 study with a 2 × 2 factorial design, conducted in 2006-2012 and enrolling 4203 participants aged 50 to 85 years at risk for progression to advanced AMD with bilateral large drusen or large drusen in 1 eye and advanced AMD in the fellow eye.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
AREDS2 10-year follow-up
“The hazard ratio (HR) for progression to late AMD comparing lutein/zeaxanthin with no lutein/zeaxanthin was 0.91 (95% CI, 0.84-0.99; P = .02)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At 10 years, the odds ratio (OR) of having lung cancer was 1.82 (95% CI, 1.06-3.12; P = .02) for those randomly assigned to beta carotene and 1.15 (95% CI, 0.79-1.66; P = .46) for lutein/zeaxanthin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vision rehabilitation and counseling: AAO Preferred Practice Pattern
Low vision rehabilitation: LOVIT randomized trial
“A total of 126 patients were included, 98% of whom were white and male.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The difference in mean changes was 2.43 logits (95% confidence interval [CI], 2.07-2.77; P < .001; effect size, 2.51) for visual reading ability” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because the waiting-list control patients demonstrated a decline in functional ability, low-vision services should be offered as early as possible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Integrated low vision and mental health care: depression prevention trial
“At 4 months, 11 BA+LVR subjects (12.6%) and 18 ST+LVR subjects (23.4%) developed a depressive disorder (relative risk [RR], 0.54; 95% CI, 0.27–1.06; P = 0.067). In planned adjusted analyses the RR was 0.51 (95% CI, 0.27–0.98; P = 0.04).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
NICE guideline NG82: support for people with visual impairment
Conjunctival monitoring and patient education after port delivery system implantation
“Ongoing assessment of conjunctival health during follow-up visits via slit-lamp assessment is critical in monitoring for potential AEs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Use of fluorescein in conjunction with a cobalt blue light may aid in identifying areas of conjunctival thinning or erosion, and serial review of longitudinal clinical images of the implantation site may be helpful in identifying new clinical findings or assessing the progression of existing ones.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, patients treated with the PDS should be educated for eye hygiene and to avoid environmental exposure, which may potentially increase the risk of endophthalmitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary
Expected outcomes are based on one completed phase 3 trial (SOL-1, Week 52) and two phase 1 trials; no peer-reviewed publication of phase 3 results and no repeat-dosing efficacy data are available. In SOL-1, among treatment-naive participants who responded to aflibercept loading, 74.1% of participants treated with a single 450 µg implant maintained vision (loss of fewer than 15 letters) at Week 36 versus 55.8% with a single aflibercept 2 mg injection, and 65.9% versus 44.2% at Week 52; 68.8% versus 47.7% were rescue-free at Week 52 under the SOL-1 rescue criteria. In a post hoc analysis applying SOL-R rescue criteria, the sponsor estimated a 72% reduction in injection burden (56% including loading doses) versus projected on-label aflibercept 2 mg every 8 weeks over 60 weeks. In the U.S. phase 1 trial of the first-generation 600 µg implant in previously treated participants, 60% were rescue-free through Month 12 and treatment burden was reduced by 89%. Expected adverse effects include vitreous floaters (12.4% versus 1.2% with aflibercept through Week 52), which the sponsor attributes to hydrogel bioresorption, and mild or moderate intraocular inflammation (9 events in 7 participants); no endophthalmitis or retinal vasculitis was reported in the implant arm. Long-term effects on fibrosis, macular atrophy, and vision beyond 2 years are unknown and are being evaluated in SOL-X (estimated 850 participants, primary completion 2030) and at Week 96 in SOL-R.
Vision maintenance with a single implant: SOL-1 primary and key secondary endpoints
Anatomic control: time to CSFT increase, post hoc analysis
Estimated treatment burden reduction: post hoc analysis
Previously treated participants: U.S. phase 1 outcomes at 12 months
Expected adverse effects: ocular adverse events through Week 52
Expected long-term outcomes: fibrosis and macular atrophy hypothesis
Long-term outcome measures in the SOL-X extension
Uncertainty in expected long-term outcomes: independent review
Patient-reported outcomes, quality of life, and repeat-dosing efficacy
No evidence found.